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This research presented here was conducted for the purpose of finding 
an effective method of treating myocardial infarction utilizing genetically 
modified mesenchymal stem cells delivered in a thermoresponsive hydrogel.  
Heart disease is the most common cause of death in the industrialized world 
and treatment still has much room for improvement.  Growth factor treatments 
have shown promise in revascularizing the infarcted tissue, provided either as a 
recombinant protein or by means of gene therapy.  Stem cells are also a means 
of treating disease that is growing in effectiveness, although cells injected to 
the heart are often plagued by poor engraftment at the injection site.   
This research is divided into three main sections.  The first deals with 
the selection of an appropriate growth factor to be used in the study.  Testing 
included quantifying the pro-angiogenic effect of the multiple growth factors 
on human endothelial cells as well as the growth factors’ effects on the 
proliferation of the cells. Plasmid DNA constructs for the growth factors of 
interest were created for use in these studies.  Growth factors were also tested 
for their influence on the mesenchymal stem cells.  It was found that none of 
the growth factors or polymers used for DNA complexation and transfection 
resulted in differentiation of the stem cells. After completing this phase of the 
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research, platelet-derived growth factor “C” was chosen for use in the 
following phases of the work.   
The second phase dealt with the characterization of a scaffold to be 
used with the transfected stem cells.  After injection of cells in saline to the 
myocardium, 90% of the cells can be lost from the injection site.  The hydrogel 
PoligoGel© from Samyang Corp. was found to be compatible with the stem 
cells, being both nontoxic, as well as not affecting differentiation of the cells. 
The final portion of the research was the application of the growth 
factor, stem cells, and scaffold in vivo in a rat model to observe the effects of 
the treatment in the infarcted heart.  Lewis rats underwent a coronary artery 
ligation to create an infarcted region of the heart. Stem cells transfected to 
express platelet-derived growth factor ‘C’ were then injected into the heart in 
a thermoreversible scaffold.  The effectiveness of the treatment was 
quantified by analyzing MRI scans of the heart, as well as the biodistribution of 
the injected cells.  
The biodistribution was performed by RT-PCR and showed a 15-fold 
increase in cells retained at the heart for groups injected with cells in a 
thermoreversible scaffold versus those injected in saline. The MRI data did not 
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 CHAPTER 1 
GENERAL INTRODUCTION, RATIONALE FOR THE STUDY, AND 
SPECIFIC AIMS 
1.1 General Introduction 
The potential of gene therapy and cell therapy is truly astounding.  
Multiple Nobel Prizes have been awarded for work in these fields(1); looking at 
just the past decade, we see it was awarded in 2008 "for the discovery and 
development of the green fluorescent protein, GFP," and in 2007 for 
“discoveries of principles for introducing specific gene modifications in mice by 
the use of embryonic stem cells” and “discoveries of principles for introducing 
specific gene modifications in mice by the use of embryonic stem cells.”  In 
2006, it was awarded for the “discovery of RNA interference - gene silencing by 
double-stranded RNA.”  In 2002, “discoveries concerning genetic regulation of 
organ development and programmed cell death” earned the Prize for Medicine 
or Physiology.  For 2001, it was awarded for “discoveries of key regulators of 
the cell cycle.”  There are also others from this time period with less direct 
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application in these fields, but still tangentially related, as well as many others 
awarded prior to 2000.   
Gene therapy focuses generally focuses on one of two avenues; first is 
introducing a new gene construct to the cell to provide a new gene, or 
secondly to augment an existing gene.  This has been used as a substitute for 
protein or peptide therapy and provides several advantages, including a longer 
therapeutic window as the half-life for the expression of the delivered gene is 
much higher than that of a protein, altered expression profile with different 
promoters, and potential for improved stability versus wild type protein by 
specific mutations in the protein (2).  The method of action for gene therapy is 
the interruption of the expression of a gene accomplished by interfering 
nucleic acids (3).   
The foreign genetic material can be introduced virally or nonvirally.   
Both methods have their limitations and advantages.  Viruses have evolved 
specifically for the delivery of DNA/RNA, and are most effective at overcoming 
the physiological and cellular barriers to gene expression.  They are, however, 
immunogenic (4).  Nonviral methods, including polymers and liposomes, are 
nonimmunogenic, and can be administered repeatedly.  The effectiveness of 
these methods still leaves much to be desired, as they are less effective at 
delivering the nucleic acids, especially to the nucleus (2, 5).  The specific 
barriers that must be overcome prior to gene expression are degradation by 
both extra- and intracellular nucleases, clearance by the immune system, 
transport across the cell membrane, escape from the endosome, and transport 
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to and into the nucleus (6-8).  These barriers are the same for gene silencing 
techniques with the exception of nuclear entry.   
Cell therapy is also showing great potential in treating many diseases. 
Stem cells can generally be divided into one of three types: embryonic stem 
cells, adult stem cells, and induced pluripotent stem cells.  Embryonic stem 
cells are capable of differentiation into any cell type in the body, given the 
right cellular signals, but suffer from some safety concerns, and much ethical 
controversy (9).  Adult stem cells are obtained from mature tissues and do not 
require the destruction of embryos for their development and use.  These cells 
are limited in their differentiative capacity, however (10).  Induced stem cells 
are adult cells that have been ‘reset’ to return to a stem cell state.  The 
‘resetting’ is accomplished by the addition of several genes or proteins which 
returns the cell to to a state resembling an embryonic stem cell in function 
(11).  Clinical trials are underway for both embryonic and adult stem cells. 
1.2 Rationale for the Study 
Ischemic heart disease is a life-threatening, debilitating condition and is 
the major cause of death in the world, accounting for nearly 30% of all deaths 
in 2002 (12).  Both gene therapy and stem cells have been used for the 
treatment of heart disease.  In vivo gene therapy has been disadvantaged by 
the increased difficulty of transfecting nondividing cells (8).  Genetic 
modification of cells in vitro prior to injection can help to alleviate this 
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setback, using the modified cells as bioreactors producing the therapeutic 
protein (13).   
Cell therapies have been hampered by the loss of cells at the injury site.  
Cells require time to attach to a substrate, and many cells can be lost to the 
surrounding tissues before they are able to join the desired tissue after being 
injected suspended in saline.  An improved delivery method of the cells has the 
potential to increase the efficacy of the treatment (14).  Here the proposed 
method is the use of a thermoreversible polymers scaffold. 
1.3 Hypothesis and Specific Aims 
The first hypothesis is that mesenchymal stem cells can effectively be 
used as a bioreactor for growth factor expression, eliciting an angiogenic 
response in endothelial cells.  The second hypothesis is that a suitable polymer 
matrix can be found which will allow for the holding of the cells in place, 
without altering their attributes as stem cells.  The final hypothesis is that the 
combined therapy of modified stem cells in an injectable polymer matrix will 
show an increased efficacy in treating ischemic heart disease.   
Testing these hypotheses was accomplished following these specific aims 
in conducting the research: 
• Plasmid vectors for various growth factors will be constructed and 
tested for their angiogenic effect on the HUVEC cell line after 
transfection of MSCs.   
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• Exploit a polymer matrix to hold the cells in place, and test the 
cells for any loss of stem cell function, while maintaining gene 
expression. 
• Use the combination of genetically modified stem cells in the 
polymer matrix in a rat infarct model to evaluate the 
effectiveness of the treatment.  
Chapter 2 in this work gives a comprehensive review of literature 
covering heart disease, stem cells, cell scaffolds, and gene therapy.  Chapter 3 
covers the construction of multiple plasmids for use in evaluating the pro-
angiogenic effect of various growth factors.  Chapter 4 details the work of 
using PoligoGel as a cell scaffold for use with stem cells.  The results for the 
combined treatment in the rat infarct model are presented in Chapter 5.  
Chapter 6 describes the future directions in which this research could be taken 
as well as the significance of the growth factor transfected mesenchymal stem 
cells for treating ischemic heart disease. 
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 CHAPTER 2  
HEART DISEASE, STEM CELLS, CELL SCAFFOLDS AND GENE 
THERAPY:  LITERATURE REVIEW 
 
 
This chapter gives an overview of primary research literature pertinent 
to the work performed and presented here. There are four primary sections 
dealing with different facets of the research. First, an overview of heart 
disease, especially ischemic heart disease, is given. This includes the 
prevalence of the disease with its associated costs, the progression of the 
disease, and also the current treatment strategies. Next, stem cells as a 
therapeutic agent are analyzed. Different sources of stem cells are given and 
compared. Third, the use of cell scaffolds both natural and synthetic are 
addressed. Finally, gene therapy is examined looking at different techniques 
for delivering new genes, viral and nonviral, as well common growth factors 
used for angiogenic treatments. 
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2.1 Heart Disease 
According to the American Heart Association (1) records, in 2006, a 
person in the United States died every 38 seconds as a result of cardiovascular 
disease. In fact, 1 in 2.8 deaths in the US is attributed to Cardiovascular 
Disease (CVD), including heart attacks and stroke. CVD has been the single 
largest killer in the US every year since 1900 with the exception of 1918. This is 
not unexpected if one considers that an estimated 1 in 3 Americans suffer from 
one or more types of CVD. Of the deaths due to CVD in 2004, 52% were due to 
coronary heart disease, with the remainder being filled in by stroke, heart 
failure, high blood pressure, arterial disease, and other. If all these major 
forms of CVD were eliminated, the US life expectancy would rise by close to 7 
years; meanwhile, eliminating cancer nets only a 3 year gain. With the 
continued rise in obesity in the Western world, this trend is unlikely to abate 
any time soon. 
2.1.1 Costs of Heart Disease 
Procedures for the treatment of cardiovascular disease numbered almost 
7 million in 2005, a 484% increase in 25 years. Catheterization is one of the 
leading treatments with 1.3 million performed in 2005 at an average cost of 
just under $27,000 per procedure. 261,000 patients were operated on for 
bypass surgery, resulting in 469,000 procedures. Heart transplants have been 
performed at a rate of about 2,200 per year over the past decade, with about 
2,700 on the waiting list. Percutaineous Coronary Intervention (PCI, also called 
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coronary angioplasty) accounted for about 1.3 million procedures in 2005; 
about 50% on those less than 65 years of age. While there has been a decline in 
hospitalization for cardiac infarct from the ‘90s, it is still above levels from the 
early 1980s (2). 
In addition to the loss of life, the monetary cost of treating CVD is 
estimated to be $502.3 billion for 2010 for both direct and indirect costs. While 
38% of those having a coronary attack suffer death as a result in any year, a 
significant portion of the expenditures is for repeat patients whose treatment 
has been insufficient to cure the root causes of the disease. In 2008, 770,000 
are estimated to have a new coronary attack and 430,000 are expected to have 
a recurrent attack. Along with the other types of CVD, over 7.2 million 
inpatient procedures were performed in 2006. Those who have previously 
survived an acute heart attack are at up to 15 times higher risk for illness and 
death, leading to additional expenditures treating and retreating the disease. 
Risk factors for heart disease are numerous, with the most common 
being smoking (3), high blood cholesterol, lack of physical activity (4), obesity 
and excessive weight (http://www.nhlbi.nih.gov/guidelines/obesity/ 
ob_gdlns.pdf), and diabetes mellitus (5). Other factors such as depression have 
also been shown to potentially contribute to the onset of heart disease (6). 
2.1.2 Indications of Disease 
By definition, ischemic heart disease is the reduced or lack of blood flow 
to the heart muscle. Coronary heart disease is the most common cause of this 
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disease. Often called angina, ischemic heart disease can benefit from early 
interventions; in the case of a total loss of blood flow, a myocardial infarction 
occurs, resulting in the loss of viable cells (7).  This loss of cells results in a 
remodeling of the heart. With the infarcted region losing contractile ability, 
the efficiency of the heart decreases. The volume of the left ventricle 
increases, and the ejection fraction decreases; this results in a stroke volume 
that is similar to the uninfarcted heart (8, 9).  Larger infarcted regions lead to 
increased rates of mortality and more significant changes in the heart 
architecture (10-13). The changes progress over time and can become 
substantially worse in the years following the ischemic event (9). 
Immediately after the triggering of the ischemic event, the now oxygen-
deprived cells begin to suffer from nutrient deprivation. In dogs, 38% of the 
affected cells were nonviable after 40 minutes, and by 24 hours, 85% were non- 
viable (14). The dead and dying cells can initiate an inflammatory response, 
which can further damage the remaining tissue as neutrophils are recruited to 
the area (15). Collagen deposition increases begin at day 2 postinfarct and peak 
at day 7 (16).  By 2 weeks, most of the initial remodeling is finished (17) .  The 
remaining changes are mostly limited to hypertrophy of the remaining 
cardiomyocytes, and a remodeling of the heart to make the wall stresses more 
uniform (18).  This irreversible damage to the heart occurs in part due to the 
lack of resident cardiac progenitor cells with the ability to repopulate the 
damaged site (19). 
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2.1.3 Current Treatment Options 
Treating IHD can be difficult. Generally, current treatment of heart 
attacks seeks to restrict the size of the ischemic/infracted area, and to treat 
symptoms.  Many additional health issues may be present which can make 
effective treatment more problematic. One of the most effective treatments 
can be a lifestyle change, especially quitting smoking, controlling cholesterol 
levels, and exercise (20, 21).  Changing lifestyle has been met with difficulties; 
some factors creating difficulty for some are a negative attitude toward own 
age and aging, not being a risk taker, low personal priority on health, health 
has previously been acceptable, chronic illness, irregular work hours or 
excessive work hours, and frequent travel (22).  Medical treatments for heart 
disease can be broken down into two classes: pharmaceutical interventions and 
surgical interventions. 
Pharmaceuticals used to treat IHD include alpha-blockers, beta-blockers, 
calcium channel blockers, nitrates, and others (23).  Alpha-blockers are used in 
the treatment of hypertension (24).  Beta-blockers are used in the treatment of 
arrhythmias (25), and have some use for hypertension (26).  Calcium channel 
blockers in addition to being effective in treating hypertension can be used to 
control heart rate, and reduce chest pain due to angina pectoris (27).  Nitrates 
are also vasodilators and are also used in the treatment of angina; nitrates 
have the added advantage of working quickly after administration (28, 29). 
Stents and balloon catheters, or bypass surgery, open the blocked 
vessels to aid in the reperfusion of the effected tissue. This treatment can help 
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alleviate the symptoms that limit the restriction of blood flow, but are not able 
to restore heart function by regenerating any lost tissue. 
Balloon angioplasty works by the insertion of a balloon catheter into the 
blocked coronary artery, typically through the femoral artery. Inflation of the 
balloon compresses the restricting plaque against the arterial walls and 
stretches the vessel.  The stretching can damage the underlying cells, perhaps 
helping the treated vessels to remain dilated (30, 31). 
Stenting the artery works in a similar way. At the time of the forced 
expansion of the vessel lumen, a metal stent is placed in the artery, holding it 
open (32). There have been many improvements with the stent, but they are 
still prone to restenosis, with early stents showing rates of up to 60% (33). All 
such treatments are also prone to restenosis if repeated to alleviate the 
symptoms of restenosis (34-37).  Even newer drug eluting devices such as the 
Cypher stent have shown similar trends at longer time points (38). 
Bypass surgery involves taking an artery or vein from a different part of 
the body to graft onto the coronary artery to bypass the blockage in that 
vessel.  While this type of surgery is effective in treating the symptoms of the 
blockage, it is far more complicated than stenting, or angioplasty (39).  Surgery 
requires the removal of a blood vessel, often from the leg, creating a second 
wound.  The heart is also stopped for the surgery, necessitating 
cardiopulmonary bypass, which is also not without risk (40). 
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2.2 Stem Cells 
As research into new and more effecting treatments has continued, one 
area that has seen significant growth in the recent past is the use of stem cells 
for the treatment of various diseases, including cardiovascular disorders (41-
45).  Stem cell work has also included bone regeneration (46), cartilage 
regeneration (47), adipose tissue (48), vascular tissue (49) and more (50-52).  
Embryonic, mesenchymal, and induced pluripotent stem cells have been used 
in these types of applications; each brings with it certain advantages and 
disadvantages. The lack of consensus is due in part to the wide range of culture 
conditions, and in the case of adult stem cells, the origin of the cells being 
used (53). 
2.2.1 Embryonic Stem Cells 
Embryonic stem cells are derived from the inner cell mast of the 
blastocyst and are capable of generating any of the three germ cell layers. 
They are self-renewing, and can be cultured indefinitely without changing 
phenotype (54). When initially isolated, they required the use of a murine 
feeder layer to maintain an undifferentiated state (55-57). This risks exposure 
of the cells to animal viruses and is undesirable for future use in vivo. More 
recently this has been overcome, and ESCs can be cultured without the need of 
a feeder layer (58-62). 
The pluripotency of ESCs allows them to become any cell type in the 
body (63), and potentially replenish any functionality that has been lost in a 
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tissue or organ. However, also due to this pluripotency, they are also capable 
of forming teratomas, tumors composed of all three germ layers, limiting their 
usefulness (54, 64) unless great care is taken to only implant cells that have 
begun to move down a differentiated pathway (65, 66).  While it is possible to 
select predifferentiated cells for implantation, differentiation along the 
desired path is typically restricted to only a few percent of the total 
population, and isolation of the proper cells can be difficult (63, 67). 
In addition to the scientific challenges in using ESCs, there are also 
ethical concerns in using embryonic stem cells (68).  Most of the opposition to 
the use of ESCs is a result of the origin of the cells, viable human embryos. For 
many, this is viewed as morally wrong and four of the major ethical concerns 
are: “(1) the moral status of the human embryo; (2) the question of complicity 
when research relies on the destruction of a developing human life; (3) the 
moral significance of medically promising alternatives; and (4) the role of law 
in a pluralistic society.” (69)  As a consequence of these unresolved moral 
questions, federal limitations exist for their use in research. These limitations 
affect the types of research that can be pursued, as well as the availability of 
funding (70). 
ESCs have been studied to replace lost myocardium, and there has been 
great success in guiding the differentiation to a cardiac-like fate (71, 72).  
However, in vivo problems are seen, such as arrhythmia (73) and teratomas 
(72).  Most therapies involving the use experience similar problems. Geron 
Corp. is set to begin clinical trials using ESC-derived cells for the treatment of 
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spinal cord injuries. The trials were delayed for a year to further investigate 
cyst formation at the site of injection in some of the previous experiments on 
mice (74). One final concern in using ESCs is the immune rejection of the cells 
after transplant. While it has been reported that ESCs are not immunogenic 
(75), this is not as true for differentiated cells, which can cause immune 
reactions (76, 77). 
2.2.2 Induced Pluripotent Stem Cells 
Induced pluripotent stem cells (IPS) are another source for cell 
treatments. IPSs require the addition of several factors to effectively reset 
them (78).  This has been accomplished by the use of viruses (79), but this 
leaves the possibility of genetic mutation in the cells if lentiviral or retroviral 
vectors are used. The use of adenoviruses and plasmid construct can be used 
without the risk of mutation to the genome, but are less efficient (80).  More 
recently, the induction of the pluripotent state has been accomplished without 
the use of viruses (80-82).  IPSs appear to have all the same characteristics that 
make embryonic stem cells so desirable; omipotency, unlimited self-renewal, 
etc. They also have the potential of being autologous to the host, removing any 
concerns over immune response. While promising, this source still requires time 
for the cells to revert to their stem cell capacity (83), and then to differentiate 
to the appropriate cell type. Treatment of ischemic disease is best 
accomplished quickly with irreversible damage occurring within hours, and 
tissue remodeling in a matter of weeks if there is a total loss of oxygenation, 
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such as in a cardiac infarction (8, 15, 18, 84).  Cells would require collection, 
induction, differentiation, and then storage until needed at a future event. 
Fast turnaround can be better accomplished with an adult stem cell. 
2.2.3 Adult Stem Cells 
Adult stem cells, also called somatic stem cells, or tissue resident stem 
cells, are multipotent stem cells that reside within fully developed tissues. 
Their main purpose is to regenerate lost or damaged tissue where they reside 
(85). Regardless of the tissue source, these cells have been shown capable of 
differentiating into different cell types, including adipocytes, chondrocytes, 
and osteoblasts (86-88). Adult stem cells have been isolated from the bone 
marrow (89), adipose tissue (90), heart tissue (91), dermal layers (92), and also 
skeletal muscle (93).  Most tissues in the body have resident stem cells (94), 
although harvesting them is not always easy or straightforward. As resident 
stem cells only account for a small fraction of the total cell population in a 
tissue, this can require a potentially large biopsy or tissue extraction to secure 
a large enough population with which to effectively work (85, 95).  While many 
people have sufficient adipose tissue for acquiring enough stem cells for a 
treatment, it would not be realistic to expect to safely obtain the same level of 
stem cells from neural, skeletal, or cardiac tissue; the resulting defect left by 
the biopsy would be problematic. Bone marrow is a source that is relatively 
simple to obtain and the isolation of the cells does not require mechanical or 
enzymatic degradation of the sample. 
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Bone marrow-derived mesenchymal stem cells are typically defined by 
their lack of CD34, CD45, CD14, and their adherence to solid surfaces(96).  
There is also a wide variety of other markers and attributes that have been 
studied and used to mark MSCs (88, 97-101).  Complications arise from the fact 
that there is no definitive marker(s) for stem cells. Some studies have used 
adherent mononuclear cells from the bone marrow (102); others use side 
populations isolated by flowcytometery (103) or other methods (98) to further 
refine the population. As a result, studies use a mixed population of cells that 
would be nearly impossible to fully characterize. 
Differences in the tissues of origin of the different cells can affect the 
differentiation capacity of the cells, giving preference to one fate more than 
another (104, 105).  Culture conditions, such as substrate hardness, are also 
able to affect the cell fate and function (106, 107). 
In multiple studies where adult stem cells from different sources have 
been injected into the heart for treating MI, there has been measurable 
significant improvement in the heart function, and decreases in the infarct size 
(41, 42, 45).  Many of the cells, however, do not have the desired fate in vivo. 
Cell death in these cases is significant, which is to be expected. They are being 
injected into ischemic regions where cell death has and is occurring as a result 
of the lack of perfusion to the area. Some have placed the cell loss as high as 
90% (108).  Cell loss in the studies had been attributed to several causes, 
including cell death, and cell migration. In addition to the cell loss, the viable 
remaining cells rarely differentiate into the most desirable cell types, 
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cardiomyocytes in the case of injection into the heart. Most often, they are 
seen as endothelial cells, smooth muscle cells, and fibroblasts. This can 
improve circulation to the surviving tissue; it does not replace the lost function 
of the defunct muscle tissue. 
2.3 Cell Scaffolds 
One of the cornerstones of tissue engineering is the use of an 
appropriate scaffold. Scaffolds must have sufficient mechanical strength for 
the cells, must be highly porous to allow for cell growth, and should not 
interfere with tissue function (109).  Scaffolds must have sufficient strength to 
support the cells’ growth, but also to mimic the extracellular matrix (110).  
Porosity of the scaffold is required for nutrient diffusion, as well as integration 
with host tissues. The ideal scaffold would also be degradable to allow for 
complete restoration of the native tissues, although with hard tissues, there 
has also been great success with biomimicry and material integration (111). 
In the treatment of MI, research has shown that the injection of a 
biopolymer gel, such as collagen, improves heart function over nontreated 
controls. The test animals had thicker ventricular walls, and better ejection 
fractions. It appears that the addition of a hydrogel to the infracted area limits 
the remodeling of the tissue that results as part of the wound healing process. 
This effect was seen without the addition of any other therapeutic measures, 
such as the inclusion of cells, or growth factors (112).  
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2.3.1 Natural Hydrogel Scaffolds 
Natural scaffolds have included fibrin (112), collagen (113), Matrigel 
(114), chitosan (115), alginates (116), and cell sheets (117).  Natural scaffolds 
resemble the native extracellular matrix, and are generally well received by 
the host.  While there are 19 or more types of collagen, they all have a similar 
structure composed of three polypeptide strands. The physical properties can 
be tuned by adding additional polymers, or by the addition of crosslinking 
agents (118).  The varying of properties has allowed collagen to be used for 
vascular tissue (119), bone (120), cartilage (121), and others (122, 123).  
Collagen is a major component of Matrigel as well. 
Fibrin has been used for a sealant and adhesive for surgical procedures 
and is one of the major components in wound healing (124).  Fibrin forms by 
the proteolytic cleavage of fibrinogen by thrombin. Fibrin gels do not exhibit 
high mechanical strength, limiting the range of possible uses without 
modification (125).  Some of the uses of fibrin gels for tissue engineering 
include neural (126), cartilage (126), and bone (127) among others. 
Chitosan is obtained from the shell of shellfish obtain from renewable 
resources. In addition to biocompatibility and biodegradability, chitosan has 
also been shown to have antibacterial (128) and wound-healing activity (129).  
There are many derivatives of chitosan to alter physical properties and tune it 
for specific applications (130, 131). 
Alginate is obtained from brown algae and has been widely used as a 
biomaterial both for tissue engineering and drug delivery. It is biocompatible, 
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has low toxicity, and also has a relative low cost (124).  Gelation is achieved by 
the addition of divalent cations. Unmodified alginate dissolves as a result of 
the diffusion of the divalent cations from the gel. This can be uncontrolled and 
unpredictable. As a result, it is often modified to better control the physical 
properties of the gel (132). 
While cell sheets are technically a scaffold-free cellular delivery vehicle, 
but have great potential for many therapies (133).  In addition to single layers 
of cells, multilayered constructs have been developed with alternating cell 
types (134). One method of generating cell sheets is growing cells to 
confluency on thermal-responsive surfaces. By lowering the temperature, the 
substrate switches from hydrophobic to hydrophilic, and the cells lose the 
ability to adhere to the surface and can be removed without any enzymatic 
action on the cells (135).  Multilayer constructs have been created and applied 
to the heart (117, 134) showing great promise. 
2.3.2 Synthetic Hydrogel Scaffolds 
Synthetic hydrogel scaffolds can be tuned for whatever requirements are 
needed for a particular application: crosslinking density (136), pore size (137), 
hydrophobicity (137), gelation mechanism (138, 139), degradation rates (140), 
and other definable properties (141). While many of these properties can also 
be modified with natural polymers, synthetics have no predefined 
characteristics, such as the backbone of chitosan, or alginate which may be 
modified but remain intact. Many of these modifications are accomplished by 
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combining natural and synthetic materials, blending the distinction between 
the two classes. Some of the most common synthetic materials are poly(acrylic 
acid) (PAA), poly(ethylene glycol) (PEG), poly(vinyl alcohol) (PVA), 
Polyphosphazene, and synthetic polypeptides. Poly(acrylic acid) has a structure 
that can be easily modified by the inclusion of different side chains on the 
monomers. Two of the most common PAA-based polymers for tissue 
engineering are poly(2-hydroxyethyl methacrylate) (HEMA) and poly(N-
isopropylacrylamide) (PNIPAAm) (124).  HEMA has been used for the 
microencapsulation of cells (142) as well as cartilage reconstruction (143).  
PNIPAAm has been used for spinal cord repair (144), cell encapsulation (145), 
and responsive surfaces for cell sheet engineering. PNIPAAm is a 
thermoresponsive polymer. The homopolymer undergoes a phase transition at 
32 degrees Celsius, moving from aqueous to a gel. Modification of the polymer 
by the inclusion of comonomers: hydrophilic monomers such as acrylic acid can 
raise the LCST (146), hydrophobic monomers like butyric acid can lower the 
LCST. The use of pH sensitive groups can also lead to additional environmental 
sensitivities to the polymer (147). 
Poly(ethylene glycol) has been widely used as a biomaterial not just as a 
hydrogel or scaffold, but also to modify small molecules to increase their 
stability, circulation time, making them less prone to proteolytic inactivation, 
and lowering toxicity, among other benefits (148).  PEG is hydrophilic, non-
toxic, chemically stable, and has modifiable hydroxyl end groups. In use as a 
scaffold, methods need to be used to crosslink the chains together. Acrylate 
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end groups are one common method of accomplishing this, allowing for photo 
initiation of the crosslinking reaction (149).  One of the reasons PEG has been 
so widely used is the relative low cost and wide commercial availability of 
different molecular weights, different end groups, and different branching 
structures; Sigma-Aldrich currently carries over 300 different PEG-based 
products. One of the major uses of PEG is combining it with different materials 
to form a composite material. Examples of copolymers include poly(propylene 
oxide) to create the poloxomers (150), poly(lactic-co-glycolic acid) (151), 
polyesters (152), as well as many natural polymers (153-155).  PEG-based and 
PEG-containing hydrogels have been used in many applications, including the 
brain (156), orthopedically (157), and with cardioprogeneter cells (158). 
Hydrogels of poly(vinyl alcohol) are typically crosslinked with 
gluteraldehyde (159), or epichlorohydrin (160).  These monomers can be toxic 
and must be washed from the gel prior to implantation (124). 
Polyphosphazenes have the advantage of being able to alter the 
degradation kinetics through modification of side groups, and not the backbone 
(161). Polyphosphazenes have also been modified (162-164) and used in many 
applications, such as skeletal regeneration (165) and cell encapsulation (166). 
2.4 Gene Therapy 
The American Society of Gene and Cell Therapy defines gene therapy as: 
“The introduction or alteration of genetic material within a cell or organism 
with the intention of curing or treating a disease.” Diseases are typically 
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treated by either replacing defective genes (167), by providing new genetic 
instructions (168), or modifying the current expression of genes (169) for the 
recipient cells. As of 2007, over 1340 clinical trials had been competed, 
approved, or started involving gene therapy (170).  The first began in 1989 
(171) treating melanoma with genetically modified lymphocytes transfected 
with a retrovirus. Monogenic diseases such as hemophilia (172), cystic fibrosis 
(173), and severe combined immunodeficiency (SCID) (174, 175) are all caused 
by a genetic mutation resulting in a single nonfunctioning protein. The 
administration of the proper gene can cure the disease by providing the 
required native protein. Cancer (176), ischemia (176, 177), cardiovascular 
disease (178), chronic wounds (179),  and more have also been treated using 
different growth factors and proteins to elicit the appropriate response from 
the host. 
There are two broad categories of agents for the delivery and 
transfection of the target cells: viral, and nonviral. Viral gene therapy replaces 
the pathogenic genes of a virus with therapeutic genes. In most cases, the virus 
is rendered replication deficient (180), but there are instances were in vivo 
viral replication is desirable (181).  Viral vectors can trigger an immune 
response in the host, which has been fatal (182).  Even if there are no 
immediate consequences, some may appear later, such as leukemia as a result 
of genomic integration (183), or immune response on subsequent 
administrations (184).  Despite the drawbacks of using viral agents for gene 
therapy, they are extremely efficient, especially when compared to nonviral 
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methods (185).  Nonviral gene therapy makes use of cationic polymers, non-
ionic polymers, lipids, mechanical interactions, and any other method that 
does not require a virus. Nonviral gene therapy generally does not have 
immunological complications, allowing for repeat administration, also, 
preparation of the particles is simpler, especially on a large scale, and is easily 
modifiable. 
2.4.1 Viral Gene Delivery 
Viruses can be very diverse; they may contain either DNA or RNA either 
single or double stranded, the genetic material may integrate or not, and they 
may be enveloped or not (183, 184, 186). In the case of replication-competent 
viruses, they may be lytic, bursting the cell on release, or lysogenic.  The most 
common viruses used in clinical trials for gene therapy are retroviruses 
(including lentivirus), adenoviruses, poxvirus, adeno-associated virus, and the 
herpes simplex virus (183).  
Retroviruses were the first viral vectors used for gene therapy. 
Retroviruses contain an RNA genome up to 8kb in size. The viral genome is 
transcribed into DNA and incorporates into the host genome. This allows for 
persistent expression of the delivered gene; however, depending on the 
location of the insertion, this can be oncogenic. Most retrovirus vectors only 
transfect dividing cells; the lentivirus is able to transfect nondividing cells 
(183, 187). 
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Adenoviruses have been modified to reduce their immunogenic potential 
(188, 189).  After entering the cell, the viral particle is carried to the nucleus 
where the double stranded DNA is transcribed. The DNA does not integrate with 
the host, but its genome is limited to less than 36 kb (187).  The biggest 
drawback to adenoviruses is their high immunogenicity. 
Adeno-associated viruses are dependent on adenoviruses for replication. 
They have a persistent transfection, but can integrate into the host genome 
(190).  These agents can only carry small amounts of DNA, less than 5kb. 
Herpes simplex virus is very potent at transfecting neural cells, where 
the transfection is persistent. Like adenoviruses, they are highly inflammatory, 
but they can carry up to 150 kb (183). 
2.4.2 Nonviral Gene Therapy 
Due to the immunogenic and mutation risks associated with viral gene 
therapy, nonviral alternatives have been researched. While viruses have 
evolved to overcome barriers to transfection and transcription of their genome, 
synthetic approaches still must overcome multiple barriers to transfect cells. 
First, they must protect the DNA as it is moving to the cell. The polyplexes 
must be stable and protected from nuclease degradation. Second, they must 
travel to the appropriate tissue and enter the desired cell. Third, once in the 
cell, they must be able to escape the endosome. Finally, after release from the 
endosome, the DNA must make it to the nucleus before it can be transcribed. 
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2.4.2.1 Overcoming Barriers to Transfection  
DNA/polymer polyplexes need to find a balance between protection of 
the DNA, and being able to release the DNA in the cytoplasm. If the complex is 
too loose, it may uncomplex in the extra cellular space, or in the case of 
systemic injection, in the blood. This exposes the DNA to nucleases and 
degradation (191).  However, if the complexes are too tight, the DNA will not 
be released in the cell (192). 
Entrance to the cell is block by the lipid bilayer that comprises the cell 
membrane. The surface of the cell membrane carries a negative charge, 
making association of positively charged particles favorable through 
electrostatic interactions (193).  Particles are then internalized by phagocytosis 
(194).  In addition to electrostatic interactions, targeting is also effectively 
used for membrane association. Antibodies or ligands can be attached to the 
polyplex, allowing the particles to be internalized by receptor- mediated 
endocytosis (195).  Lipoplexes are also potentially able to deliver their genetic 
material through membrane fusion. Membrane fusion inducers, such as 
spermine and chloroquine, can improve cellular entry (196, 197). 
The most commonly proposed method for cationic polymers to escape 
the endosome is the proton sponge effect. This hypothesis is that as the 
endosome pH drops by the addition of protons, the protons are absorbed by the 
nitrogen on the polymer, leaving the counter ion concentration to swell and 
increase the osmotic pressure in the endosome.  This leads to a rupture of the 
endosome, releasing the polyplex into the cytoplasm (198).  Fusion peptides 
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and membrane fusion inducers can also be used to aid in escape from the 
endosome (199). 
Nuclear entry is perhaps the most challenging barrier, especially in non-
dividing cells. In a dividing cell, the nuclear membrane dissolves during mitosis, 
allowing for the vector to be in the nucleus when the nuclear membrane 
reforms(200).  In nondividing cells, nuclear localization signals can be used to 
aid in transport to the nucleus (201, 202). 
2.4.2.2 Cationic Polymers for Nonviral Gene Therapy 
Polyethylenimine (PEI) is the standard for other polymers to compare 
against. Both linear and branched PEI effectively condense DNA into uniform 
particles with sizes around 100nm (203).  The structure of PEI is such that every 
third molecule on the backbone is nitrogen; this yields a highly charged 
polymer that strongly interacts with the phosphate groups on DNA (204).  The 
high charge has been associated with toxicity of the complex (205).  There are 
many derivatives of PEI that have tried to lower the toxicity of native PEI. 
Some of these modifications include PEGylation (206), cholesterol (207), and 
succinylation (208). 
One derivative of PEI that has been used is WSLP, which stands for 
water-soluble lipopolymer. Here a branched PEI with a molecular weight of 
1800 was conjugated with cholesterol chloroformate. The resulting construct is 
both effective and safe for use with a variety of cell types. It has been shown 
to be highly efficient, but does not exhibit the toxicity associated with higher 
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molecular weight PEI (207).  This polymer has been used many times in vivo to 
treat a range of diseases, including cancer (209), ischemic myocardium (210), 
erectile dysfunction (211), and neural disorders (212).  This polymer has been 
effective in the delivery of both plasmid DNA, as well as siRNA (213).   
Poly(l-lysine) (PLL) is another cationic polymer, and was one of the first 
to be used for gene therapy (214).  It is a linear polymer of the amino acid 
lysine, which makes it biodegradable; however, high molecular weight samples 
show high toxicity. It is, however, quickly bound by serum protein in vivo and 
rapidly cleared. PLL is also a poor transfection agent without modifications, 
such as the inclusion of chloroquine or other fusogenic agents (215).  PLL has 
been modified with PEG to improve circulation times (216), and also by 
substitution of histidine residues in the backbone to enhance the proton sponge 
effect after cellular uptake (217). 
A more recent polymer family constructed for use in gene therapy 
contains a bioreducible backbone with a disulfide bond. This class of polymer is 
polycationic and therefore able to complex DNA and protect it from 
degradation outside of the cell. However, after entering the cell and escaping 
the endosome, the cell reductive potential inside the cell breaks the disulfide 
bonds, allowing for the release of the DNA (218).  Many different polymers with 
the reducible backbone have been shown to be effective. CBA/DAH, which is 
composed of cystaminebisacrylamide (CBA) and 1,6-diaminohexane (DAH), 
shows high efficiency and low toxicity and has been used for the delivery of 
both DNA and siRNA (219, 220).   ABP is an arginine-grafted bioreducible 
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polymer based on CBA/DAH. ABP showed improved transfection with reduced 
toxicity. This improvement may be due to localization to the nucleus, and not 
related to cell penetration (221).  Other polymers with CBA in their backbones 
include TETA (222), pegylated TETA (223), and other small libraries of polymers 
(224). 
In addition to these well-studied polymers, others have focused their 
efforts on constructing large libraries of polymers that have yielded some 
potentially useful polymers for gene therapy (225). 
2.4.2.3 Other Methods of Nonviral Gene Therapy  
Cationic liposomes are another class of delivery vehicles. Common 
cationic lipids for inclusion in the liposome include DOTMA, DC-CHOL, and 
DOSPA; these are then mixed with DOPE or another neutral phospholipid. 
DNA/lipid complexes are also usually not as well condensed, and are also prone 
to aggregation; as such, they are often combined with cationic polymers (226, 
227).  
Other less-often-used delivery methods include naked DNA(228), non- 
ionic polymers (229, 230), and mechanical methods, including electroporation, 
ultrasound, and pressure perfusion (231). 
2.4.3 Growth Factor Gene Delivery 
Delivering genes coding for growth factors is a growing area of research. 
VEGF gene delivery alone has been used to treat a variety of illnesses, 
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including poor bronchial circulation (232), erectile dysfunction (233), hind limb 
ischemia (234), transplanted fat tissue (235), as well as others. 
2.4.3.1 VEGF 
The VEGF family of proteins is highly conserved in a wide range of 
animals, from fish to mammals (about 68% of the amino acids are identical); 
homologs can be found in even less evolved creatures such as fly, nematode, 
and jellyfish (236).  VEGF-A is the most common and contains eight exons; 
alternative splicing yields at least six different expressed isoforms with a 165 
amino acid being the most prevalent and active. All of the VEGF proteins are 
excreted. VEGF acts on two different receptors, VEGFR-1, and VEGFR-2; the 
signaling pathways for these two receptors are significantly different. Both 
receptors are tyrosine kinases, but the exact signaling pathway has not been 
conclusively determined. Both are required receptors for development; mice 
lacking VEGFR-1 or VEGFR-2 do not develop in utero past day 9.5. There is 
agreement that VEGFR-2 is the more prominent receptor for angiogenesis and 
proliferation. Treatments involving VEGF have already gone to clinical trials 
(237), and have also been delivered to the myocardium both as a plasmid 
(238), as well as via transfected myoblasts (239). 
2.4.3.2 FGF 
There are two major forms of FGF, FGF-1 and 2, also referred to as 
acidic and basic, respectively. FGF influences both proliferation and migration, 
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but uses different signaling pathways (240).  FGF is also required during 
embryonic development of the heart. Despite FGFs inducing a strong 
angiogenic response, it is generally accepted that they require VEGF to 
promote angiogenesis (241).  FGF has been effectively used in treating ischemic 
disease despite potentially requiring additional factors for best results (242). 
2.4.3.3 PDGF 
PDGF is a dimeric protein with four expressed proteins, and five 
isoforms: -AA, -BB, -AB, -CC, and –DD. The different isoforms react 
preferentially with one of two receptors: PDGF receptor alpha and beta. While 
isoforms of PDGF composed of –A and –B are excreted from the cell in active 
form, -C and –D require proteolytic cleavage in the extracellular space to be 
activated. PDGF-C has the following effects: “stimulates fibroblast 
proliferation, epithelial migration, extensive vascularization and neutrophil 
infiltration” (243). The two receptors can also dimerize, giving three different 
receptors. Each of the five PDGF isoforms has a different activation pattern on 
the receptors (244).  PDGF has also been shown to effectively treat heart 
disease (245). 
2.4.3.4 IGF 
IGF exists in two forms, IGF-I and IGF-II, each with differences in the 
signaling output after binding with their receptors. IGF-I has been shown to 
stave off apoptosis acting at several points (246).  IGF-II can promote 
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differentiation, proliferation, and is also upregulated in myocytes during 
differentiation (247).  There has long been a known association between IGF 
and angiogenesis (248). 
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CHAPTER 3  
PLASMID DNA CONSTRUCTS FOR FGF, IGF, AND PDGF-CC 
AND MSC TRANSFECTION 
3.1 Abstract 
The first step in gene therapy is selecting the gene to be used and 
preparing the construct to be used for transfection.  Plasmid DNA was utilized 
for its therapeutic effect.  Presented here is the work related to the 
construction of plasmid DNA encoding three different growth factors: fibroblast 
growth factor (FGF), insulin-like growth factor (IGF), and platelet-derived 
growth factor - C (PDGF-C).  These genes were inserted into the pCI plasmid 
backbone, which contains the CMV (cytomegalovirus) promoter, SV40 (Simian 
vacuolating virus 40) poly(A) tail, and an ampicilin resistance gene.  An 
alternate, hypoxia-induced promoter, RTP801, was also used with the PDGF-C 
gene.  Multiple polymers were also tested for use in transfecting mesenchymal 
stem cells, including the use of nuclear localization signal conjugated 
polymers.  After multiple studies, it was found that branched 
poly(ethyleneimine) (PEI) with a molecular weight of 25 kDa and an N:P ratio of 
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10:1 was the most efficient polymer for transfection.  Transfection persisted 
past 1 week while declining in intensity after 48 hours.  MSCs transfected with 
growth factors were able to induce growth responses in both HUVEC (human 
umbilical vein endothelial cell) and A7R5 (rat smooth muscle cell) cell lines, 
indicating the effectiveness of the plasmid constructs.  An in vitro angiogenesis 
assay, and proliferation assays, were utilized to help in the determination of 
which growth factor should be used in downstream applications.  Based on the 
results presented here, PDGF-C was chosen for further use. 
3.2 Introduction 
Plasmid DNA (pDNA) for the transfection of cells has been researched for 
decades (1).  It has low toxicity, does not integrate into the host genome, is 
free of any potential viral contamination, and is relatively easy to produce on a 
large scale (2).  While pDNA alone, often referred to as naked DNA, has been 
used with some success, it is more often combined with polymers or lipids for 
enhanced gene delivery (3-5).   
Plasmids are typically small, circular, double stranded DNA molecules 
that are separate from chromosomal DNA, and are capable of replication.  
Plasmids are produced by introducing the desired plasmid into Escherichia coli 
bacteria, fermentation of the bacteria, and then harvesting the pDNA from the 
cells (6). Many companies produce kits to allow for the purification of pDNA in 
quantities ranging from minipreps for isolating up to 20 "g, to gigapreps, which 
can be used for the isolation of up to 10 mg of product.   
 58 
All plasmids for cloning share some of the same features.  They require 
an origin of replication to allow for autonomous replication, and a gene for 
antibiotic resistance to allow for the selection of cells containing the plasmid.  
The third feature is the expression cassette, which includes the desired gene, a 
promoter, and a polyadenylation sequence, also referred to as the poly(A) tail 
region, which is useful for stability, nuclear export, and translation (7).  While 
not a required feature, most plasmid vectors also have a multiple cloning 
region, a sequence with multiple sites where 10 or more restriction enzymes 
are active (8).   
Restriction enzymes cleave DNA at very specific sites, often leaving 
“sticky ends,” unpaired nucleotides at the cut site.  Restriction enzymes have 
had an incredible impact in molecular biology and medicine. The Nobel Prize 
for Physiology or Medicine was awarded to Daniel Nathans, Werner Arber, and 
Hamilton Smith in 1978 for their work with restriction enzymes (9).  A DNA 
fragment can be inserted into a plasmid by cutting both DNA molecules with 
the same restriction enzymes and allowing for the combination of the two at 
the cut sites.  The cut DNA is then repaired by the use of another enzyme, 
ligase.   Using this method, it is possible to express any DNA sequence in the 
plasmid backbone (10).   
In addition to restriction enzymes, the development of polymerase chain 
reaction (PCR) has been instrumental in allowing for the cloning of therapeutic 
genes into plasmids.  The basis of PCR is in the Taq Polymerase, an enzyme for 
DNA polymerization isolated from thermophilic bacteria capable of surviving 
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temperatures above 90 Celsius, temperatures required for the denaturation of 
double stranded DNA to single strands.  There are three steps for PCR.  First is 
denaturation of the DNA to single strands.  Second is annealing; the primers 
can then attach to the parent strands of DNA by hydrogen bonding.  The third 
step is elongation, or the creation of the complimentary strand of DNA.  These 
steps are cycled, resulting in exponential growth of the target sequence (11).  
Kary Mullis was awarded the 1993 Nobel Prize in Chemistry for working out the 
principles of PCR a decade earlier (9).   
When the desired gene is known, there are several ways that the 
plasmid can be optimized for production of the gene; the promoter can be 
modified or changed, the poly(A) tail can be modified, or elements of the 
backbone of the plasmid can also be modified.  Promoters can be cell type-
specific (12), hypoxia-responsive (13), insulin-responsive (14), or responsive to 
any other physiological or environmental cue (15, 16). 
The delivery of the plasmid DNA must also be considered.  Condensation 
of the plasmid by polymers ensures protection from nucleases and efficient 
cellular uptake if designed well.  After entry into the cell, the plasmid must 
enter the nucleus in order for translation to occur, ultimately leading in 
production of the desired gene.  The use of a nuclear localization signal (NLS) 
was attempted here to improve transfection efficiency.  Other groups have 
reported some success in the use of NLS peptides conjugated directly to the 
DNA (17), as well as with liposomes (18).  The results vary greatly based on 
many factors including conjugation levels, cell type, and gene carrier.   
 60 
The growth factors being investigated vary in potency and in their 
effects on different cell types. One method of measuring their efficacy is an in 
vitro angiogenesis assay (19).  The use of recombinant protein allows for the 
comparison in a controlled environment, although care must be taken, as the 
conditions can be very different in vivo.  One of the more common assays is 
performed by sandwiching cells in a biological hydrogel scaffold, often Matrigel 
or fibrin, and then quantifying the response of the cells (20). 
The effects of growth factors on stem cells have been studied and 
yielded some conflicting results.  It is generally agreed that growth factors will 
encourage proliferation, survival, and migration of stem cells, although with 
varying degrees of efficiency for the different factors.  The propensity of the 
growth factors to induce differentiation is less understood. In the comparison 
of growth factors with similar signaling cascades, PDGF and epidermal growth 
factor (EGF) show a 90% overlap in proteins phosphorylated in human MSCs 
after exposure to the growth factors, yet only EGF elicited an osteogenic 
response (21).  This was found to be the result of a single protein, 
phosphatidylinositol 3-kinase (PI3K).  Meanwhile, the growth factor HGF was 
indicated to encourage differentiation to a cardiomyocyte phenotype (22).  
However, the differentiation was not complete, and in the authors own words 
“further differentiative steps probably require additional factors.”  Other 
studies showed that FGF would induce osteogenic differentiation, but in cells 
treated with dexamethasone (23).   
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It is unlikely that cells will differentiate into any cell type with only the 
addition of a single growth factor; at least it has not been documented.  In the 
present study, the use of growth factors is not intended as a differentiative 
agent to push the stem cells to any of the potentially beneficial cell types, but 
is only intended to promote cell proliferation and survival in both the native 
cells as well as the implanted cells.  As the MSCs integrate into the host tissue, 
they will have retained the potential to become endothelial cells, smooth 
muscle cells, cardiac cells, or other cell types, all based on the signals received 
at the injection site.   
 3.3 Materials and Methods 
3.3.1 Materials 
Restriction enzymes and the empty pCI plasmid backbone were obtained 
from Promega (Madison, WI).  Terrific broth was purchased from Fisher 
Scientific (Pittsburgh, PA).  T4 ligase, PCR reagents including Taq Polymerase 
High Fidelity, Pfx polymerase, and SuperScript® III RTS First-Strand cDNA 
Synthesis Kit were obtained from Invitrogen (Carlsbad, CA).  Agarose gel for 
electrophoreses was purchased from Promega (Madison WI).   Purification of 
PCR samples and extraction of DNA fragments from agarose gel was 
accomplished using the Wizard® SV Gel and PCR Clean-Up System from Promega 
(Madison, WI).  A cDNA library extracted from human placenta was purchased 
from Invitrogen(Carlsbad, CA).  RNA was isolated using the PureLink™ RNA Mini 
Kit from Invitrogen (Carlsbad, CA).  Plasmid purification was performed by 
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either the PureLink™ HiPure Plasmid Miniprep Kit or the Maxiprep Kit purchased 
from Invitrogen (Carlsbad, CA).  The GENEMATE Quanti-Marker 1kb DNA ladder 
was used when running an agarose gel purchased from BioExpress (Kaysville, 
UT).  DNA concentrations were measured on a NanoDrop UV-Vis from Thermo 
Scientific (Wilmington, DE).  DH5-alpha competent cells and S.O.C. media were 
purchased from Invitrogen (Carlsbad, CA).  Polyethylenimine was obtained from 
Sigma (St. Louis, MO).  All cell culture media and reagents were obtained from 
Invitrogen.  A plasmid encoding VEGF in the pCI plasmid backbone had 
previously been constructed and was used as supplied.   
The NLS peptide sequence used is n-PKKKRKVEDPYC-c, which is based off 
the SV40 virus, and has a molecular weight of 1490.79 Daltons.  The crosslinker 
used was sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate 
(Sulfo-SMCC) obtained from Pierce Protein Research Products (Rockford, IL).  
WSLP (Water-Soluble Lipopolymer) was synthesized in house as previously 
described (24).  Deuterated water for NMR and PEI were purchased from Sigma 
(St. Louis, MO).  WSLP, a PEI derivative was synthesized previously by our 
group, as published(24). 
Fibrin and thrombin were purchased from Sigma (St. Louis, MO) and 
were cell culture grade.  Recombinant human PDGF-CC was purchased from 
R&D Systems (Minneapolis, MN).  VEGF165, PDGF-BB, bFGF, HGF, and IGF were 
all purchased from PeproTech Inc (Rocky Hill, NJ). 
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3.3.2  CMV-PDGF-CC Plasmid Construction 
The CMV-PDGF-CC plasmid was constructed by placing the gene 
sequence for PDGF-CC in the pCI backbone plasmid at the HindIII and XbaI 
restriction sites.  The PDGF-CC gene is 1038 base pairs long and was isolated 
from cDNA generated from human placental tissue, which is rich with myriad 
growth factors.  The cDNA template was amplified using primers specific for 
PDGF-CC; the 5’ primer was ATA AGC TTC TCA GCC AAA TGA GCC CTC and the 
3’ primer was GCT CTA GAC TAT CCT CCT GTG CTC C.  Primers were designed 
to include restriction sites to the ends of the gene for insertion into the 
plasmid.   
Amplification was carried out according to the manufacturer’s 
instructions.  In brief, reagents were mixed to the following final 
concentrations in distilled water:  
PCR buffer – 1x, dNTPs - 0.2mN, MgSO4 – 2mM, Primers – 0.2 "M each, 
template DNA 1 "L, Platinum Taq High Fidelity – 1 unit.   
The following cycles were followed:  initial denaturation – 2 minutes, 30 cycles 
of denaturation - 30 seconds, annealing - 30 seconds, extension - 1:15 minutes, 
and a final extension of 5 minutes followed by holding at 4 degrees.   
The results of the PCR amplification were purified by running on a 1% 
agarose gel with a 1kb Quanti-Marker ladder for reference.  The band around 
1000kb was removed from the gel and purified using the Promega Gel cleanup 
kit.  The purified fragment and empty pCI plasmid were then digested 
separately using HindIII and XbaI enzymes in a double digestion.  The digestion 
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was allowed to proceed for 4 hours using the recommended conditions, 
including the use of acylated BSA.   Following the digestion, the samples were 
purified using Promega’s Wizard® SV Gel and PCR Clean-Up System.  
Concentrations were then measured using the NanoDrop, allowing for a 3:1 
insert to plasmid molar ratio.  The DNA was then allowed to react overnight at 
4 degrees with the T4 ligase for completion of the plasmid.  DH5 alpha  
competent cells were transformed using S.O.C. Medium according to the 
recommended protocol.  Cells were then placed on a LB agar plate treated 
with ampicilin (100 micro grams/mL) for screening of positive colonies.   
Five colonies were grown in 5 ml of TB broth for plasmid isolation and 
further analysis.  Colonies in TB broth were allowed to grow overnight and 
pDNA was then collected using the Miniprep Kit.  Plasmids were then run on an 
agarose gel to verify the correct plasmid size.  Results can be seen in Figure 
3.1; the two positive clones were verified by restriction enzyme digest and 
sequencing.   
3.3.3 RTP801-PDGF-CC plasmid construction 
After successful cloning of the CMV-PDGF-CC plasmid, the gene was 
inserted into a plasmid with a RTP801 promoter that shows higher response in 
hypoxic conditions.  The gene was removed from the CMV-PDGF-CC construct 
at the HindIII and XbaI restriction sites and isolated by gel electrophoresis.  The 
band for the gene was removed from the gel and purified with a gel cleanup 
kit.  The empty RTP801 plasmid was digested with the same restriction 
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enzymes and purified with a PCR cleanup kit.  The two fragments were then 
combined in a 3/1 molar ratio and ligated according to the supplied protocol.  
DHa-5 cells were transformed and selected on ampicilin agar plates.  
Identification of proper insertion of the gene into the plasmid backbone was 
confirmed by gel electrophoresis by looking at the size of the finished 
construct, as shown in Figure 3.2.  Empty plasmids and double insertions show 
incorrect sizes.  The two plasmids with the correct molecular weight were 
further confirmed by digestion.   
3.3.4   FGF Plasmid Construction 
The CMV-FGF plasmid was constructed by placing the gene sequence for 
FGF in the pCI backbone plasmid at the HindIII and XmaI restriction sites.  The 
FGF gene is 476 base pairs long and was isolated from cDNA generated from 
CADMEC cells that had been stimulated with VEGF.  RNA from the CADMEC cells 
was isolated using the PureLink™ RNA Mini Kit from invitrogen.  The cDNA 
template was amplified using primers specific for FGF; the 5’ primer was TTA 
AGC TTC TGG TGG GTG TCG GGA, and the 3’ primer was GTC TAG ATC AGC 
TCT TAG CAG ACA TTG G.  Primers were designed to introduce restriction sites 
to the ends of the gene for insertion into the plasmid.   
Amplification was carried out according to the manufacturer’s 
instructions as previous constructs.  The following cycles were followed:  initial 
denaturation – 2 minutes, - 30 cycles of denaturation - 30 seconds, annealing - 
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30 seconds, extension - 45 seconds, and a final extension of 5 minutes followed 
by holding at 4 degrees.   
The results of the PCR amplification were purified by running on a 1% 
agarose gel with a 1kb Quanti-Marker ladder for reference.  The band around 
500bp was removed from the gel and purified using the Promega Gel cleanup 
kit.  The purified fragment and empty pCI plasmid were then digested 
separately using HindIII and XbaI enzymes in a double digestion.  The digestion 
was allowed to proceed for 4 hours using the recommended conditions, 
including the use of acylated BSA.   Following the digestion, the samples were 
purified using Promega’s Wizard® SV Gel and PCR Clean-Up System.  
Concentrations were then measured using the NanoDrop allowing for a 3:1 
insert to plasmid molar ratio.  The DNA was then allowed to react overnight at 
4 degrees with the T4 ligase for completion of the plasmid.  DH5 alpha 
competent cells were transformed using S.O.C. Medium according to the 
recommended protocol.  Cells were then placed on a LB agar plate treated 
with ampicilin (100 "g/mL) for screening of positive colonies.  Positive colonies 
were grown in 10 mL of TB broth from which the plasmid was purified for 
analysis.  Verification of positive clones were verified by restriction enzyme 
digest and sequencing.  The plasmid map is shown in Figure 3.3. 
Sequencing of the plasmid showed two mutations in the FGF sequence, 
one of which altered the amino acid sequence of the protein and was corrected 
by site directed mutagenesis.  Primers for site directed mutagenesis were used 
as provided from University of Utah core facilities and were complimentary to 
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each other.  The 5’ primer was CCG TTA CCT GGC TAT G(A)A GGA AGA TGG 
AAG ATT AC with the base in parenthesis being changed from G to A.  The 3’ 
primer was the reverse compliment of the 5’ primer.  Pfx polymerase was used 
for its higher fidelity.  Multiple reactions were carried out using different 
quantities of template DNA to ensure optimal conditions.  PCR was run with an 
initial 2 denaturation at 94 degrees, followed by 12 cycles of 15 seconds for 
denaturation at 95 degrees, 1 minute at 55 degrees for annealing, and 6 
minutes at 68 degrees for elongation.  PCR samples were then purified and 
subjected to digestion with a Dpn I restriction enzyme.  Dpn I only recognizes 
and cuts methylated DNA produced in the bacteria; the synthetic DNA produced 
during PCR is not cut, leaving only the altered DNA.  The resulting plasmids 
were used to transform XL-1 blue cells.  Two colonies were obtained, one of 
which had the desired mutation back to the correct sequence.   
3.3.5 Construction of CMV-IGF Plasmid 
The CMV-IGF plasmid was constructed by placing the gene sequence for 
IGF in the pCI backbone plasmid at the HindIII and XbaI restriction sites.  The 
IGF gene is 462 base pairs long and was isolated from cDNA generated from 
human placental tissue.  The cDNA template was amplified using primers 
specific for IGF; the 5’ primer was AGA AGC TTG CAA TGG GAA AAA TCA G, and 
the 3’ primer was ATC TAG AGG GTC TTC CTA CAT CCT G.  Primers were 
designed to introduce restriction sites to the ends of the gene for insertion into 
the plasmid.   
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Amplification was carried out according to the manufacturers’ 
instructions as with previous plasmids.  The following cycles were followed:  
initial denaturation – 2 minutes, - 30 cycles of denaturation - 30 seconds, 
annealing - 30 seconds, extension - 45 seconds, and a final extension of 5 
minutes followed by holding at 4 degrees.   
The results of the PCR amplification were purified by running on a 1% 
agarose gel with a 1kb Quanti-Marker ladder for reference.  The band around 
500 bp was removed from the gel and purified using the Promega Gel cleanup 
kit.  The purified fragment and empty pCI plasmid were then digested 
separately using HindIII and XbaI enzymes in a double digestion.  The digestion 
was allowed to proceed for 4 hours using the recommended conditions, 
including the use of acylated BSA.   Following the digestion, the samples were 
purified using Promega’s Wizard® SV Gel and PCR Clean-Up System.  
Concentrations were then measured using the NanoDrop, allowing for a 3:1 
insert to plasmid molar ratio.  The DNA was then allowed to react overnight at 
4 degrees with the T4 ligase for completion of the plasmid.  DH5 alpha  
competent cells were transformed using S.O.C. Medium according to the 
recommended protocol.  Cells were then placed on a LB agar plate treated 
with ampicilin (100 micro grams/mL) for screening of positive colonies.  
Positive colonies were grown in 10 mL of TB broth from which the plasmid was 
purified for analysis.  Verification of positive clones were verified by restriction 
enzyme digest and sequencing.  A map of the plasmid construct can be seen in 
Figure 3.4. 
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3.3.6  NLS to Polymer Conjugation 
The conjugation of the SV40 NLS peptide to WSLP took place in the 
following manner.  5mg of bPEI was dissolved in deionized water and the pH 
was adjusted to 7.4 by the addition of dilute HCl.  The crosslinker sulfo-SMCC 
(1.7 mg) was dissolved in 0.25 mL DMF and added to the polymer.  SMCC was 
allowed to react with WSLP for 90 minutes at room temperature where the NHS 
ester on the crosslinker reacts with primary amines on the polymer.  After the 
crosslinker and polymer had reacted, the NLS peptide (10.8 mg) was added to 
the reaction vessel and allowed to react overnight. The resulting polymer was 
then purified by dialyses for 3 days against deionized water with frequent 
replacement of the dialysate.    
3.3.7 Cell Culture 
 MSCs were cultured in MEM-alpha supplemented with 20% FBS and 1x 
antibiotics.  When the cells reached 80-90% confluency, they would be split 3-
1.  Media is exchanged every 3-4 days.  Passaging cells was accomplished by the 
removal of the growth media, washing twice with PBS.  The addition of Tripsin 
0.25% and EDTA was added and allowed to incubate at 37 degrees for 5 
minutes, or until the cells had lifted off the plate.  Cells were used prior to 
passage 10.   
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3.3.8 Transfection 
 For transfection, cells are plated on standard tissue culture surfaces and 
allowed to grow to 50% confluency or less.  Standard growth media was 
replaced with serum-free media and the DNA complexes were added.  After 4 
hours, the media was exchanged with standard growth media.  Cells were 
allowed to incubate as normal until further analyzed.   
DNA complexes were formed at a final DNA concentration of 0.05 
mg/mL.  Two "g of DNA were added to one well on a standard six well plate, 
with 2 mL of media in the well: roughly one microgram per 100,000 cells. 
Complexes were formed by mixing a polymer solution with a DNA-containing 
solution.  DNA solutions were composed of 5% glucose in water and DNA at a 
concentration of 0.10 mg/mL.  Polymer solutions were 5% glucose in water with 
a polymer concentration appropriate for creating the proper N/P ratio for the 
complex.   Typical N/P ratios are from 5:1 and up, depending on the polymer 
being used.  A 10:1 N/P ratio for PEI would require a polymer concentration of 
0.03 mg/mL.   
3.3.9 Cell Viability 
 Cell viability was measured by an MTT (MTT (3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide)) assay.  Cells were grown and transfected 
as described in Section 2.2.7.  After incubation for 24-48 hours, MTT was added 
to a final concentration of 0.2 mg/mL.  Cells were allowed to incubate for 3-4 
hours to allow the MTT to be converted to an insoluble formazan crystal.  After 
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incubation, the media was aspirated off the cells and DMSO was added to 
dissolve the crystals.  The concentration was then measured on a 
spectrophotometer reading at 570nm.   
3.3.10 In Vitro Angiogenesis Assay 
Fibrin gels were formed by first reconstituting fibrinogen and thrombin 
at concentrations of 10 mg/ml and 100 units/ml, respectively.  These solutions 
were then mixed in a variety of final combinations from 6.6 mg/ml fibrinogen 
to 1.5 mg/ml, and final thrombin concentrations from 40 units to 1 unit, to see 
which formed the most transparent gel for ease of analyzing the cell 
structures.  The optimized fibrin gel contained 4 mg/ml fibrin, and 40 units of 
thrombin, and was used for the assay.  HUVECs were placed in a 96 well plate 
above 50 ml of the fibrin gel and allowed to grow overnight.  A second layer of 
50 ml was then placed above the cells.  Once the gel was set, supplemented 
growth media was added to the wells.  Media was supplemented with high and 
low concentrations of the growth factor of interest.  Cells were analyzed 
following 72 hours of growth.  Analysis was performed by taking a photograph 
of the cells in a random field in each well and looking at the morphological 
structure of the cells; each field was scored from 0-5. The scores breakdown as 
follows: 0 = no cell interactions, 1 = minimal cell migration and alignment, 2 = 
capillary tubes begin to form, 3 = sprouting of new tubes visible, 4 = closed 
polygons of cells visible, and 5 = a complex mesh of closed structures visible.  
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The results are the average of 6 scored images and were analyzed by a one-way 
ANOVA with Bonferroni posttests.    
3.4 Results 
3.4.1 Plasmid Construction 
All of the plasmids were successfully constructed as verified by 
sequencing of the gene of interest, as well as by restriction enzyme digestion.  
Genes showed perfect alignment to sequences given in the NIH GenBank 
database for IGF and FGF; the accession numbers are as follows: for IGF 
NM_000618, for FGF NM_002006.  The accession number for PDGF-C is 
NM_016205.2 and initially showed a single base mutation altering the amino 
acid sequence.  Site-directed mutagenesis performed on the CMV-FGF plasmid 
was successful; sequencing the gene a second time showed perfect alignment 
with the published sequence.   
3.4.2 NLS Conjugation 
The conjugation of the NLS peptide to the WSLP backbone yielded 3.5 
mg of final product, a 20% yield based on the total weight of all the reactants.  
NMR was used to calculate the conjugation ratios of polymer to NLS peptide.  
WSLP has peaks around 2.5 to 3.0 corresponding to the hydrogen on the PEI 
backbone, while the tyrosine residues on the NLS peptide show peaks at 7.1 
and 6.7.  Comparing the ratios of these peaks, the estimated conjugation ratio 
is 59%.  The estimated molecular weight based on the conjugation ratio is 2874 
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g/mol.  The NMR spectrum for the purified product can be seen in Figure 3.5.  
All peaks resulting from the tyrosine on the peptide were assumed to be 
chemically conjugated, as free peptide would have been lost during the dialysis 
purification of the polymer. 
3.4.3 Polymer Transfection 
Multiple polymers were tested for ability to transfect and also for 
cellular toxicity.  Some of the polymers used were branched and linear PEI, 
WSLP, and NLS conjugated PEI with N:P ratios ranging from 5:1 to 30:1 
depending on the polymer.   Results for the MTT assay and luciferase 
transfection can be seen in Figure 3.6.  Error bars on the graph are the 
standard deviation with n=3.  The experiments were conducted on 6-well 
plates.   
As expected, increasing polymer concentration resulted in higher 
toxicity within polymer groups. Gene expression also increased with polymer 
concentration with the NLS and PEI polymer groups; WSLP did not show 
increased transfection, most likely due to the significant toxicity on these 
cells.  Highest transfection with a luciferase reporter gene plasmid was seen 
with PEI at an N:P ratio of 20:1 (p<0.001).  This combination also showed 
significant toxicity.  The best choices were PEI at 10:1 or WSLP at 10:1.  Repeat 
experiments using GFP expressing plasmid, and flow cytometry analysis, 
showed PEI 10:1 outperforming WSLP 10:1 both in luminescence and in the 
percentage of cells transfected, and both being upstaged by the NLS 
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conjugated PEI at 20:1, as seen in Figure 3.7.  The NLS-conjugated polymer had 
significant toxicity based on the flow cytometry data; as a result, PEI 10:1 was 
used for future experiments.    
Transfections were also shown to persist with gene expression 
decreasing, but continuing, past 7 days, as shown in Figure 3.8.  Days 1 and 2 
were significantly different from day 7 (p<0.05).  Changing the oxygen levels 
also gave the anticipated result with gene mRNA levels dropping with the CMV 
promoter under hypoxic conditions and rising with the use of the RTP801 
promoter, data shown in Figure 3.9.  Here the hypoxia-responsive promoter 
only gave a two-fold increase in expression levels, and the changes were not 
statistically significant. 
3.4.4 In Vitro Angiogenesis Assay 
The in vitro angiogenesis assay was accomplished by sandwiching 
HUVECs between two layers of a fibrin gel.  Gels with final concentrations of 4 
mg/ml fibrin and 40 units of thrombin were observed to have the best optical 
properties for visualizing the cells in the gel.  In the initial assay, all of the 
growth factors were used at two different concentrations, 1.5 times the ED50, 
and 3 times the ED50.  VEGF and PDGF-C were both found to produce more 
efficient responses, and were further used with transfected MSCs.  The results 
for the HUVECs exposed to transfected MSCs are given in Figure 3.10, showing 
PDGF-CC and VEGF each outperforming the other growth factors with no 
statistical difference between the two.   
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3.4.4 Response to Expressed Genes After Transfection 
In order to test the ability of the expressed proteins to generate a 
growth response, transfected stem cells were placed in well inserts over human 
umbilical vein endothelial cells (HUVECs); results are given in Figure 3.11.  The 
growth factors FGF, VEGF, and PDGF-C, as well as a Luciferase plasmid, were 
all tested and compared to cells with just media.  PDGF-C was statistically 
different from all other groups with a p-value of < 0.001 as calculated with 
ANOVA and Bonferroni posttest.  As mature blood vessels contain more than 
just endothelial cells, tests were repeated using A7R5 cells, rat aorta smooth 
muscle cells; results are given in Figure 3.12.  However, for this test, media 
was transferred from one well to another, as opposed to using inserts. 
 
3.5 Discussion 
The transfection of cells has two primary concerns.  First are the 
characteristics of the gene expression, predominantly the duration of 
expression and the expression level.  If expression drops off from the elevated 
levels too quickly, there may not be enough time for an appropriate response 
to take place.  If the elevated gene expression is too high, or persists too long, 
the unwanted side effects can occur, such as the formation of angiomas when 
working with growth factors.  It is also possible for the local concentration of 
the growth factor to become high enough to saturate cell receptors, interfering 
with a cell’s ability to sense the direction of the gradient, and as a result may 
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not be capable of responding to the signal.   The second factor is toxicity 
caused by the polymers used for delivery.  Cationic polymers have been shown 
to be toxic, and are more toxic with increased molecular weight and 
concentration.  However, larger polymer chains and higher concentrations are 
more efficient at condensing DNA.  The balance must be found between 
expression levels and toxicity.  Here that balance was found to be with PEI at 
an N:P ratio of 10:1.  Different cell lines will show different sensitivities to 
some polymers, and must be looked at individually. 
Testing of various polymers with the MSCs indicated that bPEI was the 
most effective polymer for transfection.  While the NLS containing polymer 
showed higher transfection efficiency, with an excreted protein, total 
production is of more importance than the number of producing cells.  The 
toxicity associated with the higher concentrations was also a deterrent to using 
the NLS polymer.  While all polymers tested were able to transfect the MSCs to 
some degree, none outperformed branched PEI.   
The hypothesis that the NLS peptide would improve transfection was 
correct in that a larger population of cells did express the gene.  But taken as a 
whole, the cell population was not producing the protein at higher levels, and 
for a protein released from the cell, total expression is of greater relevance 
than the number of producing cells.  While the direct cause was not studied, it 
was noted that the use of the NLS polymer resulted in only minimal numbers of 
outliers producing multiple times higher signals for GFP signals when compared 
to PEI.  Refinements to the NLS-polymer conjugates were attempted, but 
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without added success.  Different conjugating agents were tried, specifically 
sulfo-SMCC and PEG 3400.  The peptide was conjugated to both PEI and WSLP.  
Despite these different attempts, there was no significant improvement over 
the base polymer for any of the combinations.  While these results were 
disappointing, most others have also been met with limited if any success (25).   
Plasmids for the expression of multiple growth factors were created and 
tested in MSCs and on HUVEC cell lines. The creation of plasmids driven by the 
CMV promoter and encoding the growth factors PDGF-C, FGF, and IGF was 
satisfactorily completed based on the sequencing of the genes.   The ability of 
the plasmids to elicit a positive growth and angiogenic response as a result of 
transfection also confirmed the positive construction of the plasmids.  While 
both PDGF and VEGF showed angiogenic responses, both as indicated by the 
angiogenesis assay as well as HUVEC proliferation, only PDGF showed a positive 
response for smooth muscle cells.  In the A7R5 smooth muscle cells, VEGF-
treated cells actually showed lower proliferation than the control cells.  With 
the exception of capillaries, mature blood vessels require both endothelial cells 
as well as smooth muscle cells.  For the revascularization of the heart, which is 
the end goal, blood vessels larger than capillaries will be required.  PDGF was 
chosen for further study as an outcome of the results presented here. In the 
case that PDGF proves inadequate at a later point in the study, VEGF would be 
the replacement candidate of choice.  As referenced earlier, VEGF has been 
used successfully in generating an angiogenic response, both in the heart and 
elsewhere in the body.   
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While less desirable, it would also be a possibility to inject both cells 
and plasmid DNA complexes at the same time into the infarcted region.  This 
would potentially provide the benefit of both the stem cells, as well as an 
increased cell population for transfection resulting in protein production.  Also 
of note is that when transfecting resident cells, they are unlikely to wash from 
the area, meaning that protein produced by them will be concentrated at the 
site of the injury.   
3.6 Conclusion 
PDGF was designated as the best growth factor with which to proceed 
for further study.  While this is based on the results of multiple experiments, it 
is also exciting due to the novelty of working with PDGF-C which has not been 
known and studied as long as other growth factors, such as VEGF or FGF.  The 
plasmid will be delivered after complexation with branched PEI 25k.  While 
disappointing that the NLS conjugations were in vain, PEI has a long and proven 
track record in conjugations, and while toxicity is a concern with this polymer, 
cell death was minimal and the concentration of 10:1.  Additionally, the 
transfection will be done in vitro prior to injection of the cells, so systemic 
toxicity will not be an issue.   
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Figure 3.1 Schematic presentation of the pCMV-PDGF-C plasmid showing 
the ampicilin resistance (AmpR), the F1 and ColE1 origins of replication, the 
CMV promoter and cAMP response elements, the IGF gene, restriction enzyme 
cut sites, and the poly(A) tail from the SV40 virus. 
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Figure 3.2 Gel electrophoresis of plasmids obtained from positive 
colonies.  L = DNA Ladder (number indicates base pairs), 1-5 indicates different 
positive selected colonies.  2 and 5 demonstrate a single band at the 






Figure 3.3. Schematic presentation of the pCMV-FGF plasmid showing 
the ampicilin resistance (AmpR), the F1 and ColE1 origins of replication, the 
CMV promoter and cAMP response elements, the FGF gene, restriction enzyme 





Figure 3.4 Schematic presentation of the pCMV-IGF plasmid showing the 
ampicilin resistance (AmpR), the F1 and ColE1 origins of replication, the CMV 
promoter and cAMP response elements, the IGF gene, restriction enzyme cut 





Figure 3.5 NMR spectrum of NLS conjugated to WSLP.  The peaks at 7.1 
and 6.7 correspond to the tyrosine residues on the NLS peptide, the peaks from 
3.5 to 2 are from the PEI, and the peaks between 2 and 1 are from the 






Figure 3.6 Toxicity (top) and luminescence (bottom) after transfection of 
MSCs with a CMV-luciferase plasmid complexed with multiple polymers and 
multiple N:P ratios.  Viability measured by MTT assay and normalized to control 
wells.  Luminescence is reported as Relative Light Units (RLU) where measured 
light intensity has been normalized to total protein content.  Error bars are the 
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Figure 3.7 Comparison of polymer conjugates for transfection and 
toxicity.  A) MSCs transfected with a CMV-GFP plasmid showed highest 
transfection with NLS conjugated PEI 25k 20:1 based both on the total percent 
of the cells transfected as well as the total florescence.  There was no 
statistical difference between bPEI and the NLS conjugation.  B) Despite the 
higher transfection, the NLS PEI also had higher associated toxicity for the 20:1 




Figure 3.8 Transfection of MSCs persisted past 7 days when transfected 
with a CMV-luciferase plasmid.  Relative Light Units (RLU) is the total 
luminescence divided by the total protein concentration (mg).  Error bars are 









Figure 3.9 The RTP801 promoter is hypoxia responsive and results in 
upregulated gene expression when the cell experiences hypoxic conditions.  
Here it is shown to roughly double the expression of PDGF in MSCs.  Data were 
collected by PCR comparing to beta-actin.  Error bars are the standard 








Figure 3.10 Angiogenic potential of different growth factor as 
recombinant protein.  HUVECs were sandwiched between layers of fibrin.  MSCs 
were transfected with growth factor encoding plasmids, embedded in PoligoGel 
and placed over the HUVECs. Cells were allowed to grow for 72 hours; no media 
was replenished during that time.  After the incubation period, MSCs were 
washed off with cold PBS and the HUVECs were imaged and cell organization 
was analyzed and quantified.   The scores breakdown as follows: 0 = no cell 
interactions, 1 = minimal cell migration and alignment, 2 = capillary tubes 
begin to form, 3 = sprouting of new tubes visible, 4 = closed polygons of cells 




Figure 3.11 HUVECs co-cultured with transfected MSCs were shown to 
grow most significantly in the presence of PDGF-CC transfected cells. PDGF-C 
cells were significantly different from all others with p<0.001, as measured by 






Figure 3.12 Proliferation of A7R5 rat aorta smooth muscle cells with 
media transfer from transfected MSCs.  Media was transferred twice over 3 
days.  The control group was defined as 100% growth, and the growth factors 
were compared to that group.  Error bars are the standard deviation with n=3.  
There was no statistical difference as measured by ANOVA. 
  
CHAPTER 4  
POLIGOGEL AS A CELL SCAFFOLD 
4.1 Abstract 
The concept of stem cells as a therapeutic agent has been gaining 
momentum.  A common mode of administration of these cells is by direct 
injection into the target tissue.  This can result in many of the cells being lost 
due to reflux from the injection site, leading to a local loss of implanted cells.  
PoligoGel is a nontoxic hydrogel with an LCST near body temperature.  It is also 
shown to be nontoxic to multiple cell types, and in the case of rat 
mesenchymal stem cells does not alter their differentiative capacity, either by 
inducing differentiation, or limiting the potential for subsequent differentiation 
after removal from the gel.  Embedding cells in PoligoGel also does not 
interfere with the cells ability to delivery therapeutic growth factors post-
transfection with plasmid DNA.  Here a thermoresponsive hydrogel, PoligoGel, 
is shown to have potential to act as a scaffold for the retention of cells at an 
injection site, mitigating migration or washing of the cells away from the 
target site after implantation. 
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4.2 Introduction 
Cell-based treatment for disease is growing in scope and effectiveness.  
Uses currently range from neural therapies (1), to heart treatments (2), and to 
cartilage (3).  This has increased the need to develop delivery strategies that 
are able to maximize the potential of these cellular treatments. This is 
especially true in the case of autografts, where limited numbers of cells can be 
isolated and a fast turnaround time is often key (4).  While the use of cells 
suspended in saline is commonly demonstrated in studies, it is not perfect; only 
a limited number of cells may engraft at the implant site.  One study found 
only 10% of injected cells were retained 30 minutes after a myocardial 
injection (5).  The authors concluded by commenting on the need of furthering 
the development of strategies to retain the cells where needed.    
Bone marrow-derived MSCs have been known for over a decade to have 
the potential for differentiating into multiple cell types (6).  This cell type can 
be obtained from the bone marrow by aspiration, resulting in a large number of 
collected cells that do not require harsh enzymatic treatment to isolate from 
the host tissue, or intensive isolation procedures.   In many instances, all that 
is required is simply taking the adherent fraction of mononuclear cells; this 
does result in some heterogeneity in the population, however (7). 
Scaffolding systems seeded with cells is one method for limiting the 
departure of implanted cells from the target area.  Seeded scaffolds have been 
accomplished by the use of preformed scaffolds (8), or injectable in situ 
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forming scaffolds which may be stiff (9) or more often a hydrogel (10, 11).  Cell 
sheets have also been used with success (12).   
Hydrogels are ideal candidates for soft tissue as they are supple, and 
generally perform well from a biocompatibility perspective.  Hydrogels can also 
be tailored by altering the crosslink density, the pore size, degradability, 
stiffness, and other parameters in order to achieve the requisite properties 
(13).  Hydrogels have long been used as a biomaterial for local deliver of small 
molecules, including examples from the late 1970s (14). Stimuli-sensitive 
polymers have also been used in this fashion (15).  More recently, in situ gelling 
hydrogels have been used to deliver various molecules such as steroids, 
proteins, and chemotherapy agents (10, 16-18).   Materials undergoing gelation 
in situ are especially useful due to the ease of delivery, a simple injection.  
Hydrogels which gel via chemical crosslinking have potential drawbacks, 
including reactivity of active groups with host tissues, leachable small 
molecules, monomer or initiator, limited working time for injection prior to 
gelation, or the need for additional equipment, such as a uv source.   
In comparison stimuli-sensitive, and specifically thermoresponsive, 
hydrogels do not have these drawbacks. However, they can be significantly 
more difficult to customize without skewing the hydrophilic/hydrophobic 
balance and altering the LCST.  The lack of covalent crosslinking also tends to 
yield less mechanically stable materials.  Temperature and pH change can be 
used to initiate a phase change in these polymers leading to gelation, 
independently, or used in conjunction with success (16, 19).  Temperature-
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sensitive polymers have been widely studied (20, 21).  Some of these polymers, 
such as pluronic F127, have successfully been used for drug delivery, but have 
met with difficulty when used for cell encapsulation where the amphiphilic 
nature of the polymers can lead to membrane destabilization resulting in cell 
death (22).  
PoligoGel is a novel degradable thermosensitive hydrogel manufactured 
by SamYang Corp. of Korea covered by United States Patent number 7,655,735.  
As described in the patent, it is based on multiple alternating blocks of PEG 
and PPO or PBO joined by degradable dicarboxilic linkages and has an LCST 
near physiological temperatures.  The general chemical structure of PoligoGel 
is M-X –O-[PEO-Y-PEO-C(=O)-R-C(=O)-0]n-PEO-Y-PEO-O-X-M where M is either H 
or an anion, Y is either PPO or PBO, R is (CH2)m with m being an integer from 0 
to 20, and n is an integer from 1-100. The structure of the variety of PoligoGel 
used for this experiment is given in Figure 4.1. Variations in the structure 
modify the LCST of the resulting solution.   The LCST is also dependent on the 
concentration of the polymer in solution; a 15% gel will form near 20ºC, a 10% 
gel near 25ºC, and a 5% gel near 32ºC.   In addition to the LCST being 
dependent on the concentration, the gel stiffness also varies, with lower 
concentrations yielding lower stiffnesses.  The 5% gel at body temperature is a 
soft gel that will not flow, but does deform under its own weight.  The delivery 
of multiple different small molecules has been achieved in vivo with the use of 
PoligoGel, including interferon-alpha over 5 days, human growth hormone over 
6 days, and granulocyte stimulating factor over 8 days.   
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PoligoGel is nontoxic to multiple cell lines including rMSCs, human 
umbilical vein endothelial cells (HUVECs), and mouse colon carcinoma (CT-26), 
and in the case of rMSCs does not influence their pluripotency. Here it is shown 
to be a suitable material for the delivery of bone marrow-derived rat 
mesenchymal stem cells (rMSCs).  Cells in the gel remain viable for over 7 days, 
are able to express protein when transfected while in the gel, and should 
escape the gel as it degrades.  When used with transfected MSCs, excreted 
growth factors are able to diffuse from the gel and elicit a growth response in 
HUVECs, allowing for a wide range of potential treatments. 
4.3 Materials and Methods 
  Rat mesenchymal stem cells were obtained from Tulane University’s 
Center for Gene Therapy and expanded as recommended.  In brief, cells were 
grown in Minimum Essential Media alpha (Invitrogen, Catalog number 12561-
056), supplemented with 20% FBS (biowest, Catalog number S01520) and 1x 
Penicillin/Streptomyosin (Invitrogen, Catalog number 15140-122).  Media was 
exchanged every 3-4 days.  Cells for expansion were plated at approximately 
100 cells/cm^2.  Cells are passaged at a confluency of 70-90%.   To lift the 
cells, they are washed in PBS and incubated in TrypLE™ Express (Invitrogen, 
Catalog number 12605-010) for 5 minutes, or until detached from the plate.  
CT-26 cells were grown in RPMI-1640, 10% FBS and 1x Penicillin/Streptomyosin, 
but otherwise cultured the same as the MSCs.  HUVEC cells were grown in EGM-
2 BulletKit media (Lonza CC-3162) used as supplied.  Cells were passaged at 
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90% confluency, and media was refreshed every 2-3 days.  Primary cells were 
used at passage numbers 10 or less.   
MTT assays were performed by adding MTT to fresh growth media to a 
final concentration of 0.2mg/mL.  Cells were incubated for 3-4 hours at 37°C 
5% CO2 to allow the conversion of MTT to formazan crystals in the mitochondria 
of the viable cells.  The media was then removed, and the cells were washed 
with PBS.  The formazan crystals were then dissolved with DMSO and the 
absorbance was read on a plate reader (BioRad Model 680) at 570nm.   
Trypan Blue 0.4% (Sigma, T-8154) was added to cells in suspension at a 
1:1 ratio.  The mixture was allowed to incubate at room temperature for 5 
minutes, after which live and dead cells were counted on a hemocytometer.   
Cell viability by alamarBlue was accomplished according to the 
manufactures instructions.  Briefly, cells were plated in white clear bottom 96-
well plates.  At the required time points, 10x alamarBlue was added to the 
culture media and allowed to incubate for between 4 hours and overnight, 
depending on the cell concentration.  Plates were then read on a PerkinElmer 
LS 55 Luminescence Spectrometer. 
Fibrin gels were prepared in the following manner.  Fibrin powder 
(Sigma, F2629-5g) was reconstituted in PBS by adding the fibrin to the top of 
the PBS in a 50ml tube with gentle rocking and allowed to dissolve.  Fibrin 
concentrations were calculated to be near 10mg/ml using uv/vis.  Thrombin 
(Sigma, T4648) was reconstituted in PBS at 100 units/ml and stored at -20°C 
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until used.  Gels were made in 96-well plates by adding 20 uL thrombin to 30 
uL fibrin solution.   
The following procedure was followed for differentiation.  Cells were 
grown to confluency in 6-well plates prior to adding the appropriate induction 
media.  For osteogenic differentiation, it included complete media 
supplemented with 10mM !-glycerol phosphate, 50 "g/ml ascorbic acid, and 
100nM dexamethazone; media was refreshed every 3-4 days.  Adipogenic 
differentiation media was used as reported by Winer et al. (23).  Induction 
media consisted of growth media supplemented with 1 µM dexamethasone, 
200µM indomethacin, 10 µg/mL insulin, and 0.5mM 3-isobutyl-1-
methylxanthine, which was placed on the cells for 3 days, followed by 
maintenance media (complete media with 10µg/ml insulin) for 1 day.  This 
cycle was repeated twice, for a total of 8 days.  All of the supplements used 
were obtained from Sigma, and were cell culture tested.   
PoligoGel (SamYang Corp.) was obtained in a lyophilized cake.  To 
hydrate the polymer, it was mixed with unsupplemented growth media or PBS 
and stirred overnight at 4°C to make a 10% w/v solution.  For suspending cells 
in the gel, a 10% PoligoGel solution was mixed at 4 °C 1:1 with cells suspended 
in complete media to give a 5% polymer solution and the desired concentration 
of cells.  The 5% solution was then placed in a cell culture incubator at 37 °C.  
5% final solutions were used unless otherwise noted. Properties of 5% gels are 
mechanically sufficient for cell delivery without the added viscosity and 
associated difficulty of working with higher fraction gels. 
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For SEM analysis, samples were prepared by flash freezing in liquid 
nitrogen, followed by lyophilization.   Samples were then imaged on a FEI 
Quanta 600 FEG.   
RNA was isolated from rMSCs using TRIzol reagent (Invitrogen, 15596-
018).  cDNA was created with SuperScript III First-Strand (Invitrogen, 18080-
051) using oligo DT primers following the recommended protocol.  PCR for 
amplification of the genes of interest was performed using either Kapa2G Fast 
PCR Kit or the Hot Start kit (KapaBiosystems).  Primers used for amplification 
are listed in Table 1. 
Cells were grown in standard culture conditions to roughly 50% 
confluency.  The cells were then transfected in serum free media and allowed 
to incubate for 4 hours, after which they were placed back in standard growth 
media or embedded in a 5% PoligoGel as described above.  Cells were 
transfected with branched Poly(ethyleneimine) at an N:P ratio of 10:1.   
4.4 Results 
Viability of cell types tested was not affected by the presence of 
PoligoGel at any of the concentrations tested.  PoligoGel was tested on rMSCs, 
CT-26 (mouse colon cancer) cells, and Human Umbilical Vein Endothelial Cells 
(HUVECs).  In all cases, the same trend was observed: no toxicity at nongelling 
concentrations of 0.1%, 0.5%, and 1% to a 5% or 10% gel.  In each case, there 
was no statistical difference by MTT assay at nongelling concentrations.  At 5% 
or higher solutions, the cells under the gel did not proliferate, but remained 
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viable as measured by Trypan blue.  When confluent cells that were no longer 
actively dividing were used, there was no significant difference between the 
control and experimental groups, as shown in Figure 4.2.  Experimental groups 
were normalized to samples without the use of PoligoGel; three replicates 
were used for each group. 
When suspended in PoligoGel, rMSC do not suffer any significant cell 
death.  For these studies, cells were tripsonized, pelletted, resuspended in 
growth media, and placed on ice to lower the temperature.  The cooled cell 
suspension was then mixed with PoligoGel, also cooled on ice, to achieve final 
concentrations of 100k, 200k, 500k, and 1 million cells per milliliter and 
polymer concentrations of 5%.  500uL of the gel/cell mixtures were then placed 
in a 24-well plate.   After 48 hours, cells were removed from the gel by cooling 
the gel and adding sufficient media or PBS to lower the total concentration of 
polymer to prevent a gel from reforming. The mixture was then removed from 
the well and centrifuged at 400 rcf for 5 minutes to pellet the cells, which 
were resuspended in growth media and analyzed with trypan blue. The 
viabilities ranged from 95% at 100k per ml to 85% at 1 million per ml.   
Cells embedded in PoligoGel show a spherical morphology with no visible 
protrusion into the gel when viewed by light microscopy, not the typical 
spindle shape seen when cultured on substrates such as fibrin with sites for cell 
binding.  They also do not appear to proliferate based on the observation that 
cells remain suspended and are typically seen independent of other cells, not 
forming clusters as would be expected for dividing cells unable to migrate 
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through the substrate.   Scanning electron microscopy confirms this, with cells 
appearing to be encased in the polymer, in stark contrast to cells grown in or 
on a fibrin gel where cells can be seen to attach and spread, resulting in a 
spindle shape as seen in Figure 4.3.  Cells removed from the gel and plated in 
standard tissue culture dishes were able to resume proliferation, as seen when 
differentiating cells removed from the gel. 
When culturing stem cells, others have observed that the substrate 
properties influence cell fate along different differentiative pathways (23).  
Substrate properties are also important for other cell types as well (24, 25).  
MSCs growing in PoligoGel are exposed to a soft three-dimensional scaffold; 
they then undergo a halt in proliferation, and an induced morphological 
change. It was possible that cellular capacity to differentiate was effected.  To 
ensure that PoligoGel does not push rMSCs to differentiated fates, cells were 
cultured for 1 week suspended in the gel at about 100k cells/ml before being 
removed.  Cells were then placed in differentiation media, or had the RNA 
immediately collected for PCR analysis following removal from the gel.  Cells 
induced to an adipogenic fate were confirmed to develop into adipocytes by 
both the presence of lipid droplets in the cells (data not shown), as well as 
expression of genes indicative of an adipocyte phenotype.  Control cells 
removed from the gel not placed in adipogenic induction media did not express 
the genetic markers for adipocytes, either immediately upon removal or at the 
time the induced cells were analyzed. While it would be unlikely for the soft 
gel substrate to induce differentiation of the cells to a hard tissue, the 
 103 
retained capacity to do so does allow for the confirmation of the cells’ retained 
pluripotency.  When treated with osteogenic media, cells removed from 
PoligoGel changed from a spindle shaped morphology to a more cuboidal shape.  
Cells were also harvested for RNA collection at the end of the incubation 
period for PCR analysis.  Cells were positive for both osteogenic markers. 
Peroxisome proliferator activated receptor # (PPAR- #) and Adipocyte P2 
(aP2) were measured for adipogenic differentiation, and for bone Osteoblastic 
specific factor-2 also known as Runx2 (OSF-2) and Osteocalcin (OCN).  For each 
pair, the first gene is an early marker and the second gene is a later marker for 
differentiation along that path.  The early markers may be constitutively 
expressed at low levels.  Cells removed from PoligoGel did not exhibit either of 
the late differentiation markers, but there was some up regulation in the 
expression of PPAR-# in the cells removed from the gel.  Differentiated cells 
did express both RNAs with or without incubation in the gel.  PCR results 
looking for the different marker genes are shown in Figure 4.4. 
PoligoGel was also tested for its effects on protein expression in 
transfected cells.   MSCs were transfected with a luciferase encoding plasmid 
and 4 hours posttransfection were removed and placed in PoligoGel, or 
replated in a standard cell culture environment.  Luciferase expression was 
observed at 2 and 4 days posttransfection.  Cells were also allowed to persist in 
PoligoGel for 2 days, and were then removed from the gel and placed in a 
standard tissue culture dish.  No difference was seen between cells within, or 
without PoligoGel, as seen in Figure 4.5.   
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The ability of transfected rMSCs to elicit a growth response was tested 
on HUVECs.  As previously mentioned, cells grown under gelled PoligoGel did 
not proliferate.  To avoid this effect, HUVECs were plated in 96 well plates, 
and 50 uL of a fibrin gel was placed on top of the cells.  MSC growth media was 
added to the wells after the fibrin had form a gel, and allowed to sit overnight.  
The following day, the excess media was removed by inverting the plate over 
sterile gauze, allowing the media to drain by gravity.  Transfected MSCs were 
mixed in PoligoGel 4 hours posttransfection, and 200 uL of the gel were added 
to each well.  The cell concentration was approximately 100-200k cells/mL.  
After 48 hours for cell growth, the plates were placed at 4 degrees C for 5 
minutes and had 200mL cold PBS added.  The MSCs and excess PoligoGel were 
then removed by inverting the culture plate over sterile gauze.  200 uL of 
growth media were then added, above the fibrin gel and HUVEC cells.  Alamar 
blue was then used to assay the number of cells in each well.  As seen in Figure 
4.6, all groups outperformed the HUVEC only control, and all growth factor 
transfected groups outperformed the addition of unaltered stem cells.   
The persistence of the transfection was observed with PCR and is shown 
in Figure 4.7.  All transfections showed elevated mRNA levels of gene 
expression beginning at 4 hours and continuing to 3 days, with higher levels 
observed for FGF and VEGF at 7 days as well.  Also of note is that the initial 
FGF transfection seems to have promoted an increase in the transcription of 
VEGF, and transfection with any of the three growth factors, but not a 
luciferase control, increased FGF mRNA levels.  VEGF-transfected cells 
 105 
continued to show increased FGF mRNA at 3 days out as well.  By day 7, the 
expression levels had dropped back down near the levels of the control cells.   
4.5 Discussion 
Cell treatments will never reach their full potential if the cells fail to 
persist at the intended target.  Cells are lost to washout from the injected site, 
migration, and cell death.  Here it has been demonstrated that the use of a 
thermoresponsive hydrogel has the potential to be used for the in vivo delivery 
of cells.  The use of the gel can reduce the loss of cells from the implant site 
due to washout and migration by forming a hydrogel scaffold that will hold 
cells near the injection site where they will be able to affect the desired 
tissues, both directly as the gel degrades and cells are able to escape, and 
indirectly by releasing growth factors both constitutively or by means of 
transfection.  PoligoGel can be used to potentially reduce the number of cells 
required for injection by keeping a greater proportion of the cells nearby.  
While MSCs derived from bone marrow are relatively plentiful and easy to 
obtain, this benefit should not be over looked, especially for allografts of cells 
such as cardiomyoblasts, where yields are lower and more difficult to obtain 
(26). 
PoligoGel was also shown to be nontoxic at low concentrations to 
multiple cell types although proliferation was adversely affected when a gel 
was formed above the cells.  Mesenchymal stem cells suspended in the gel 
suffered no significant adverse consequences at cell concentration up to 1 
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million cells per ml.  Cell viability remained high, above 90%, and dropped to 
84% at the higher concentration.  This cell death is not assumed to be due to 
PoligoGel or the encapsulation process, but rather due to lack of diffusion of 
oxygen and metabolites for cells farther from the surface resulting in necrosis, 
but this was not tested. Cells also do not appear to proliferate in the gel, based 
on the observation that cells remain suspended and are typically seen 
independent of other cells, not forming clusters as would be expected for 
dividing cells unable to migrate through the substrate.   Studies using direct 
cell transplantations have used far greater numbers of cells for the injection, 
typically in the tens to hundreds of millions in humans(27).  This would require 
far greater cell loading than would be practical with this system, but with the 
cells fixed in position, it is possible to have equivalent if not greater numbers 
of cells near the requisite site.  
Maintaining viable cells is only part of the difficulty in using stem cells.  
The cells must retain their differentiative capacity in order to achieve the full 
therapeutic potential.  PoligoGel does not have any observed effect on 
mesenchymal stem cells’ ability to differentiate after 1 week of being exposed 
to the gel, either by pushing the cells to a differentiated fate, or limiting their 
ability to become terminally differentiated cell types. This allows for local 
cellular signals at the implant site to push the stem cells to differentiate into 
suitable cell types for wound healing, whether that is endothelial cell or 
smooth muscle cell for revascularization, or cardiomyocytes for replacing cells 
which may have died during the ischemic event. 
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Transfected cells can improve the outcome by delivering growth factors 
that can recruit additional cells to the tissues and also promote survival of the 
native cells.  The use of PoligoGel does not impair the effectiveness of the 
transfection.  Transfected cells suspended in the gel were able to elicit a 
growth response from HUVECs; a luciferase assay further confirmed no 
statistical difference in protein production between cells in the gel and those 
on standard surfaces (data not shown).  Looking at mRNA expression 
demonstrated a typical expression profile with a peak at 3 days, and expression 
levels returning to control after 7 days.  While the mRNA levels are not 
indicative of the levels of protein expression, it does indicate that the plasmids 
are active, and the translation is occurring.  While both FGF and VEGF appear 
to be stimulating the production of the other growth factor, the growth factor 
used in transfection showed the highest expression.  Alone or included with 
PoligoGel, none of the growth factors demonstrated any superiority over the 
others in regards to differentiative capacity of the cells; regardless of 
treatment, all the cells retained the ability to differentiate into adipocytes, or 
osteoblasts.  While looking at HUVEC proliferation, there was no statistical 
difference between the different growth factors; PDGF-CC did show the highest 
proliferation.  This in combination with the data from the previous chapter 
showing PDGF-CC and VEGF as having the highest angiogenic potential 
demonstrates the viability of using PDGF-CC as an appropriate choice for 
transfection of the MSCs to be implanted in the heart.   
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4.6 Conclusions 
With the growing number of cell therapies being tested and developed, 
it is important to ensure that the cells are being used to the greatest 
advantage.   The thermoreversible polymer PoligoGel has been shown to have 
the potential to be used for the delivery of stem cells.  It does not influence 
stem cell differentiation and permits cell survival past 1 week when cells are 
imbedded in the gel.  Despite spherical morphologies when in the gel, 
transfected cells embedded in the gel have been shown to be able to produce 
therapeutic proteins after transfection.  Protein from transfected MSCs can be 
delivered from the gel, eliciting a growth response in other cell types.  The use 
of this material has the potential to improve current cell treatments by 
retaining the cells at the site of implantation.  As previously mentioned, a 
majority of the cells injected in saline are lost in as little as 30 minutes (5). 
The use of the scaffold will allow the expressed proteins to act at the implant 
site, as opposed to tissues where they eventually may engraft. 
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Figure 4.1 Representative structure of PoligoGel.  PoligoGel is composed 
of alternating blocks of poly(ethylene oxide) and poly(propylene oxide) joined 
by ester bonds with a small hydrocarbon chain.  For the gel used, the average 
values for the repeat units were n = 101, m = 56, p = 2, and q = 7.  
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Table 4.1:  List of primers used in PCR for amplification of target genes.   
Gene Forward Primer Reverse Primer 
aP2 AAT TCG GCA CGA CTC CTT GAA AGC 
TGG TCG ACT TTC CAT CCC 
ACT TCT 
PPAR-" TCT CCA GCA TTT CTG CTC CAC ACT 
ATA CAA ATG CTT TGC CAG 
GGC TCG 
Runx2 CAA GTG CGG TGC AAA CTT TCT CCA  
TGT TTG ACG CCA TAG TCC 
CTC CTT 
Osteocalsin AAT GCC ACT GCG TAT TGG TTG ACG  
TGG CGG TGA GAT AAT GGA 
TGT GGT 
GADPH GAC CCC TTC ATT GAC CTC AAC TAC 
AGA TGA TGA CCC TTT TGG 
CTC C 
VEGF GCC AGC ACA TAG GAG AGA TGA G 
GCT TGT CAC ATC TGCA 
AGTA CG 
FGF CAA GCA GAA GAG AGA GGA GTT GTG TC 
TCA GCT CTT AGC AGA CAT 
TGG AAG 






Figure 4.2: While the gel does not induce cell death, as confirmed by 
trypan blue staining, it does limit proliferation.  When placed above confluent 
cells, there is no change against confluent controls.  Variations in the 
subconfluent values are based on differences in the initial number of cells 







Figure 4.3: Images of rMSCs on PoligoGel and Fibrin Gels.  a) Image taken 
with a light microscope with cells in PoligoGel 5%, b) light microscope image of 
rMSCs growing on a fibrin gel, c) SEM image of rMSCs embedded in PoligoGel, d) 
fibrin gel with rMSCs.  While the fibrin promotes cell attachment and 
spreading, no evidence is seen of cell attachment in the PoligoGel samples.  
Arrows indicate the location of cells in the corresponding matrix.  Scale bars 




Figure 4.4:  MSC differentiation did not occur as a result of exposure to 
PoligoGel at either a 5% or 10% concentration, although they did express low 
levels of some factors compared to control groups.  Cont – Control cells grown 
on standard tissue culture surfaces; 5% - Cells grown in 5% PoligoGel; 10% - 
Cells grown in 10% PoligoGel; Diff – Control cells exposed to differentiation 
media without prior exposure to PoligoGel.  Cells removed from PoligoGel 
retained the ability to differentiate, as evidenced by production of both 




Figure 4.5 Transfected cells were placed in PoligoGel (Gel), or replated  
(Luciferase) after transfection with a luciferase encoding plasmid.   Gel 2+2 
indicates cells that were first placed in PoligoGel for 2 days, and then grown in 
standard conditions for the following 2 days.  There was no difference between 




Figure 4.6:  All transfected groups were significantly improved over 
HUVEC only group (p< 0.05), which was given a value of 1 for comparison to the 
other groups. PDGF-C was significantly different from all nongrowth factor sets 
at p< 0.05, the difference was not significant between the growth factor 
transfected groups.   Data are the average of 6 wells; error bars are the 
standard deviation.  Data were analyzed by ANOVA with Bonferroni posttests to 





Figure 4.7:  PCR data showing the expression of various growth factors 
both constitutively and as a result of transfection.  Rows are genes of interest, 
and columns show the gene with which the cells were transfected if applicable.  
Elevated mRNA levels were seen for both FGF and VEGF out to 7 days, with 







IN VIVO STUDY OF EFFICACY OF TRANSFECTED MSCS FOR 
THE TREATMENT OF CARDIAC INFARCT IN A RAT MODEL 
5.1 Abstract 
Heart failure is marked by the loss of viable tissue and the formation of 
scar tissue at the site of impaired blood flow.  This scarring results in negative 
remodeling of the heart to achieve the same ejection volume, while equalizing 
the stresses in the heart.  This results in ventricle dilation and hypertrophy of 
the still viable muscle.  Mesenchymal stem cells can be used as a therapeutic 
device in treating heart disease.  Cell delivery is impaired by the loss of cells at 
the injection site.  A tissue scaffold has been used to retain cells at the heart, 
to allow for a longer, more effective treatment window. MSCs can help foster 
angiogenesis, helping to restore lost blood flow.  In addition to the cells 
integration into the myocardium, they have also been transfected to express 
PDGF-CC.  PDGF-C is an angiogenic factor, stimulates the release of VEGF, and 
helps contribute to mature newly formed blood vessels.   
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Testing of the proposed treatment was accomplished in a rat coronary 
infarct model. The heart was accessed via thoracotomy, after which the left 
coronary artery was ligated.  The treatments were given shortly after the 
ligation.  Animals were analyzed by cineMRI to observe the heart function.  The 
biodistribution of the cells was also examined by PCR; test animals were all 
female, and the injected cells were from male rats, allowing for the 
measurement of genes associated with the y-chromosome.   
There was no significance observed in the MRI data, for ejection 
fraction, wall thickness, heart volume, or stroke volume.  Biodistribution 
showed an increase of over 15 times more cells in heart for groups where the 
cells were delivered with a scaffold. 
5.2 Introduction 
The prevalence of cardiovascular disease has necessitated significant 
research into new treatments for recovery after ischemic events.  One of the 
major limitations in treating patients who have suffered a heart attack is the 
lack of regeneration of cardiac tissue.  This results in remodeling of the heart 
to retain the same ejection volume as prior to the infarct, and equalizing 
stresses in the wall of the heart (1-3).  Many of the newest treatments focus on 
repopulation of the myocardium and preservation of cells in the ischemic 
region to minimize tissue loss.  Repopulation of the heart has been attempted 
by cell injection (4-6), cell sheets (7), as well as recruitment of cells to the 
infarct site (8). Cells injected in saline have a low engraftment rate, and most 
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end up at sites away from their needed location.  Cell sheets do not suffer from 
this limitation, but do require significantly more time and equipment for their 
creation, if autografts are used.  Neither cell sheet autografts, nor relying on 
the recruitment of native cells to the myocardium, would be of use in the 
initial period of wall thinning and dilation of the ventricle, which occur in the 
initial 72 hours (3).    
In addition to repopulation, effort is directed to the prevention of 
cardiomyocyte death.  Many of the gene therapies for treating heart ischemia 
have focused on the delivery of anti-apoptotic cytokines, many of which are 
also angiogenic, or by the silencing of apoptotic factors (9).  Gene delivery to 
the myocardium has focused on several different targets based in part on 
differences in the time from the ischemic event.  In treating the heart shortly 
after the ischemic event, most of the work has been focused on saving tissue 
and the restoration of adequate blood flow.  Some of the most common genes 
used are growth factors, such as vascular endothelial growth factor (VEGF), 
fibroblast growth factor (FGF), hepatocyte growth factor (HGF), and platelet 
derived growth factor (PDGF).  These genes are typically delivered directly to 
the heart to transfect local cells by means of intramyocardial injections, 
catheter-based perfusion, ultrasound targeted microbubble destruction, or 
retroinfusion (10).  Injecting therapeutic plasmid DNA has been shown to be 
effective as a treatment for myocardial infarction.  When used in a rabbit 
model where the circumflex artery was ligated to produce an infarct in the 
heart, the untreated animals developed an infarct of nearly half of the 
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ventricle.  Animals treated with a VEGF plasmid delivered by a cationic 
polymer developed an infarct of roughly 15% of the left ventricle (11).    
Transfected cells used to deliver growth factors to the myocardium have 
also yielded promising results. Myoblasts transfected with VEGF encoding 
plasmid restored function to the heart following transplantation into the 
ischemic myocardium.  This was measured by observing the ejection fraction, 
wall thickness, and end systolic and diastolic volumes (12).  The use of MSCs 
with VEGF has also shown to be myogenic and prevent the progression of heart 
dysfunction (13). 
Genes are also being targeted for silencing.  Shutting off of correct 
genes can lead to increased survival of myocardial tissue in the ischemic 
region. While growth factors often have some anti-apoptotic effects, other 
proteins such as Bcl-2 can be much more potent at achieving cell survival (14).  
Hif-1a is a transcription factor which when expressed at higher levels can lead 
to increased expression of many genes, including genes regulating apoptosis 
and resistance to oxidative stress (15).   
Scaffolds have also been used, and shown to have beneficial effects on 
the ischemic heart (16, 17).  The combined use of transfected stem cells 
retained at the heart by the use of an in situ forming hydrogel has the 
potential for improving the efficacy of treating myocardial infarction, as is 
shown here in a rat model. 
There are multiple factors that can be analyzed to study heart function.  
Those observed here by MRI are the ejection fraction, wall thickness, and heart 
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volumes.  Ejection fraction is the measurement of the fraction of the blood 
that is pumped out of the heart with each beat; it is a measurement of how 
efficiently the heart is working.  Wall thickness can be used to observe scar 
formation as well as remodeling of the heart.  The heart volume is also a 
measure of the remodeling that has occurred in the heart. 
5.3 Materials and Methods 
5.3.1 Cell Culture 
Rat mesenchymal stem cells were grown in Minimum Essential Media 
alpha (Invitrogen, Catalog number 12561-056), supplemented with 20% FBS 
(biowest, Catalog number S01520) and 1x Penicillin/Streptomyosin (Invitrogen, 
Catalog number 15140-122).  Media was exchanged every 3-4 days.  Cells for 
expansion were plated at approximately 100 cells/cm^2.  Cells are passaged at 
a confluency of 70-90%.   To lift the cells, they are washed in PBS and 
incubated in TrypLE™ Express (Invitrogen, Catalog number 12605-010) for 5 
minutes, or until detached from the plate.   
PoligoGel was mixed in MEM – alpha overnight at 4 degrees for a final 
concentration of 10% W/V, and sterile filtered prior to use.  Cells were 
suspended in MEM-alpha at a concentration of 2 million/mL and subsequently 
mixed with 10% PoligoGel, giving final concentrations of 1 million cells per mL, 
and 5% PoligoGel. Cell/gel mixes were loaded into syringes, and stored at 4 
degrees in a refrigerator until use in the animals.  Transfection was performed 
on cells at about 50% confluency in serum free media and allowed to incubate 
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for 4 hours, after which they were placed back in standard growth media or gel 
mixed with growth media.  Cells were transfected with branched 
Poly(ethyleneimine) at an N:P ratio of 10:1.  Cells were used for surgery 24 
hours after transfection. 
5.3.2 Animal Model 
The following materials were required for animal surgeries:  16 g 
(BD381457) 1$ in for endotracheal tube, guide wire, surgical tape (3M 1527-1), 
syringe (TB, 1, 0.5cc), alcohol wipes, needle (30g), providone-iodine wipes, 10 
x 10 cm2 gauze, 5 x 5 cm2 gauze, EKG machine with EKG electrode needles (3), 
pulse oximeter, scale, animal hair clipper, ventilator, small scissors, 0 silk 
suture for tying the endotracheal tube around the neck, optical fiber light 
source, spatula, intubation board, ear punch, hair cap, sterile gloves, and 
surgical masks. 
The sterile instrument tray included one of the following unless noted 
differently: finger-loop locking (Wheatlander) retractor, scalpel holder for #10 
blade, needle driver, hemostats (2), long fine forceps, dish for saline, cutting 
scissors, dissecting scissors (Metzenbaum), 10 x 10 cm2 gauze (4-5), 5 x 5 cm2 
gauze (4-5), cotton tip applicator (10), blue towel (2).  These additional 
accessories were also used: 3.0 vicryl suture (1 per rat), 6.0 prolene suture (% 
per rat, for ligation), normal saline (for the dish), #10 surgical blade, 30g 
needle (1 per rat, for injection only) (BD305106), TB syringe (BD309602).   
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Medications for the animals included Ketamine, Atropine, Cefazolin, and 
Buprenorphine.  Ketamine was dosed at 44mg/Kg and injecting intramuscularly.  
Atropine was dosed at 0.02-0.05mg/kg and injected intramuscularly.  Cefazolin 
was reconstituted at 0.1g/ml and 0.25 ml was administered by intraperitoneal 
injection.  Buprenorphine at 0.3mg/mL was administered intramuscularly at 
0.01-0.05 mg/Kg.   Lidocane (2%) was used to numb the throat prior to 
intubation. 
The rat infarct model was executed in the following manner.  Female 
Lewis rats weighing 190-220 g were anesthetized in an induction chamber with 
isoflurane at 4%.  Once the animal was asleep, ketamine was injected into the 
right thigh, the ear was punched for identification, and the hair was shaved 
from the left anteriolateral chest using animal clippers.  The animal was then 
returned to the induction chamber with oxygen only to awake; 10 minutes were 
allowed to pass to ensure the ketamine had taken effect. Isoflurane (4%) is 
again used to sedate the animal prior to intubation.  Once asleep, the rat is 
given the proper doses of both atropine and cefazolin.   
Intubation was performed in the following manner. The IV catheter had 
a small section of tubing slid up the outside of the catheter to a distance of 
about 1cm from the end.  The guide wire was then inserted through the 
catheter.  The rat was hung by the incisors on an intubation board.  The tongue 
was drawn from the mouth using the cotton end of an applicator, and held out 
of the mouth with the other hand.  The stick end of applicator was then used 
to hold the tongue out of the way, and the mouth open.  A second applicator 
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was used to apply lidocaine to the throat and vocal cords and massage them 
open.  The guide wire was inserted into the larynx, the catheter slid down the 
wire into place and the guide wire removed.  Proper placement was checked 
for using a clean polished spatula to observe condensation from the exhaled 
breath.   
Once proper placement of the endotracheal tube is obtained, the animal 
is transferred to the surgery table, carefully holding the tube in place.  After 
checking the proper placement of the endotracheal tube again, 0 silk suture is 
used to tie the catheter around the head to prevent movement.  The animal is 
then hooked to the ventilator and the ventilator is started with 3% isoflurane.   
The left arm of the rat is taped above the head, the pulse oximeter and 
EKG are attached and signals obtained.  The shaved portion of the chest is 
cleaned with the providine-iodine wipes. 
The technique used for the operations is descrbed here.  Once in sterile 
surgical gear, a blue towel is draped over the rat and a small 4x4 cm hole is cut 
in the towel, exposing the shaved area on the animal.  The heartbeat is felt 
through the chest wall, and using the scalpel, an incision is made at the 
inferior location where the heart is felt strongest. Using the scissors, the 
muscle layers were cut down to the rib cage.  Once to the ribs, the lower 
intercostal space where the heartbeat can best be felt is entered.  After 
carefully entering the thoracic cavity, the intercostal space is spread with the 
retractors.   
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A small portion of a gauze sponge is moistened and used to sweep the 
lung out of the way.  The pericardium is then cut away from the heart.  After 
finding the left anterior descending artery, it is ligated with a single stitch 
using 6.0 Prolene suture.  If the infarct size was insufficient a second stitch was 
used closer to the aorta.  The appropriate treatment was then applied to the 
infarct zone.  After removing the gauze, the chest is sewn closed in three 
layers using 3.0 Vicryl.  First, the ribs are closed using a figure-of-eight suture.  
Second the muscle layers are closed with a running stitch.  Finally, the skin is 
closed using a running subcuticular stitch.  Once the rat was breathing on its 
own, and the blood oxygenation was stable above 75%, the animal was moved 
to a cage under a heat lamp.   
5.3.3 MRI Analysis 
CINE MRI analysis was performed on a Bruker Biospec 7T/30cm system 
using Bruker AVANCE II electronics.  Transmission and reception were achieved 
using a Bruker birdcage quadrature resonator with a 72 mm inner diameter. 
Animals were imaged 4 weeks postsurgery.  Animals undergoing imaging 
were anesthetized using isoflurane, 4% for induction, and maintenance at 2.5%.  
Rats were monitored using a pulse-oximeter attached to the hind paw, and a 
pressure sensor to monitor respiration.  Body temperature was monitored by a 
rectal thermometer, and controlled by a warm air heater.    
Gating for the images was accomplished by the use of IntraGate 
software package from Bruker.  Slices were taken from the apex of the heart to 
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the top of the ventricles in 1.5 mm slices with 15 time increments dividing a 
single heartbeat.  The resolution of a single frame was 0.26 mm on the x-axis, 
and 0.15 mm along the y-axis based on the size of the pixels.  An example 
image is given in Figure 5.1, a slice taken from a rat receiving cells in PoligoGel 
as a treatment.  Images are shown for both the native image, as well as with 
contours drawn which were used for analysis.  Analysis of the resultant images 
was accomplished using the freely available software packages Segment v1.8.  
The left ventricle was analyzed for ejection fraction, wall thickness, and 
ventricular volume.   
5.3.4 Biodistribution 
Biodistribution is being performed by RT-PCR.  All the animals used are 
female, and the cells being injected are from male rats.  This allows for cells 
to be tracked in the animal by looking for genes specific to the ‘Y’-
chromosome, the sex-linked region ‘Y’.  Multiple controls will be used in the 
analysis, to minimize differences in expression between tissues.  Genes to be 
used for controls include beta actin, cyclin-dependent kinase inhibitor 1B 
(CDK1b), cyclin-dependent kinase inhibitor 1A (CDK1a), hypoxanthine 
phosphoribosyltransferase 1 (HPRT1), E74-like factor 1, and eukaryotic 
translation initiation factor 2B, subunit 1 alpha.  The control genes were 
amplified using master mixes obtained from Applied Biosystems (Carlsbad 
California) and used as purchased, catalog numbers Rn00667869_m1, 
Rn00582195_m1, Rn00589996_m1, Rn01527840_m1, Rn00585356_m1, and 
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Rn00596951_m1, respectively.  Primers and probe for the SRY sequence were 
purchased from Applied Biosystems and designed using the Primer Express 
software program using accession number NM_012772.1.  The primers used 
were GGC GCA AGT TGG CTC AA for the forward primer, GGC AAC TTC ACG 
CTG CAA for the reverse primer, and AGA ATC CCA GCA TGC AGA was used for 
the Taqman probe.   PCR was performed using TaqMan® RNA-to-CT™ 1-Step Kit, 
part number 4392938, on an Applied Biosystems StepOnePlus machine.  RNA 
was loaded at 100 ng per well.   
Tissues were harvested after 24 hours.  Rats were sacrificed by 
isoflurane overdose after an injection of heparin.  The abdominal wall was 
opened and the aorta severed.  As the organs of interest were removed, they 
were immediately frozen in liquid nitrogen.  Tissues were stored at -70ºC until 
homogenized with a mortar and pestle.  In the case of the heart, the tissue was 
thawed with RNAlater-ICE (Applied Biosystems, AM7030) for removal of the left 
ventricle, then homogenized.   
5.4 Results 
A total of 34 animals were used for the MRI analysis.  Some animals had 
insufficient infarcts to be included in experimental groups.  Ejection fraction 
was used as the excluding factor; animals with an ejection fraction over 70% 
were not used for analysis in the experimental groups where an infarct was 
presumed to have been caused.  All groups had 5-6 animals in the set.    
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5.4.1 MRI Analysis Results 
After successful application of the coronary ligation model, imaging was 
performed at 4 weeks (an average of 29 days) postinfarct.  The resulting scans 
were then analyzed using Segment software.  The ejection fractions for the 
rats are given in Figure 5.2.  The average ejection fraction for the non-
infarcted heart was 78.1% ± 1.4.  The ligation only group had an average 
ejection fraction of 45.9% ± 14.2.  Transfected cells had an average of 52.1% ± 
9.4.  PoligoGel alone showed an average of 51.0% ± 15.5.  PoligoGel with 
untransfected stem cells had an average ejection fraction of 50.9% ± 14.1.  The 
PoligoGel with transfected stem cells yielded an average of 47.6% ± 11.7.  
There was no statistical difference between any of the infarcted groups based 
on a one-way ANOVA analysis. 
Wall thickness was also calculated based on the MRI images.  The 
thickness was calculated by the Segment Software package after manually 
tracing the surfaces of the heart.  The thickness was calculated across 8 
segments of the myocardium.  Segments 1-3 were typically healthy tissue.  
Segments 4-6 included the septum.  Segments 7 and 8 typically were composed 
of the infracted zone with segment 8 being more fully infarcted tissue.  This 
measurement was more challenging to perform due to poorer quality of the 
epicardial surfaces compared to the endocardial surfaces at some areas of the 
heart.  A typical thickness for a healthy heart is around 3mm; an infarcted 
tissue can lose 1-2 mm in thickness (12).  The results are given for both systolic 
and diastolic thicknesses in Figure 5.3.  Viable, contractile heart tissue will 
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thicken as a result of the contraction, while scar tissue will have no such 
change in morphology.  The lack of thickening can be seen in Figure 5.4 where 
the change in thickness for sector 8, the predominately infarcted sector, is 
given.  There is little contractibility in the infarcted hearts, but no significant 
difference between the treatment groups. The final parameter gained from the 
MRI analysis of the hearts was the heart’s end systolic and diastolic volumes.  
Figure 5.5 shows the volumes for the various treatments.  There were again no 
significant differences.  The stroke volumes, however, did show differences, 
with all groups different from the thoracotomy alone, as seen in Figure 5.6.   
5.4.2 Biodistribution 
Of the many different potential controls evaluated for use, beta actin, 
CDK1b, and HPRT1 were found to be the most consistent in achieving proper 
amplification across the range of tissues.   
Tissues examined included the left ventricle, the remainder of the 
heart, kidney, spleen, bone marrow, liver, and lung.  Cell numbers were 
approximated by mixing cells with processed heart tissue in known amounts 
corresponding to 1 million cells per gram of heart tissue, down to 100 cells per 
gram of heart tissue and then generating a regression curve from the results. 
Real-time PCR showed that cells delivered in PoligoGel were retained at 
a significantly higher level than those injected without the gel.  The left 
ventricle showed almost 850,000 cells per gram of tissue for cells injected with 
PoligoGel while the cells alone were retained at a rate of about 55,000 cells 
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per gram.  The results were significant with p < 0.001.  A slight number of cells 
were found in the lung of one of the animals with no PoligoGel used, but there 
was no other definitive discovery of cells in any of the other tissues with either 
set. 
5.5 Discussion 
The variance in the infarct size prevented statistical significance from 
being realized in the MRI data despite others having used this model as a viable 
method of testing in vivo.   There are several possible reasons for this 
discrepancy.  First, while performing the procedures on the animals, greater 
precision in the placement of the ligating suture would have been beneficial.  
Ligation was typically performed where the artery was most visible, and not 
based on landmarks on the heart, such as the aorta.  The slight variations in 
the anatomy of the hearts of individual rats and slight variations in the surgical 
entry point which led to a lack of uniformity in the ligation site could have 
been ameliorated by additional practice, especially with one more familiar 
with the procedure.  Even with the surgeries as performed, this lack of 
consistency might have been alleviated with multiple measures of each animal 
and analyzing the data with a repeat measures ANOVA looking for the 
improvement in the hearts, or the lessening of the hearts deterioration.  Larger 
groups of animals would also have helped to acquire lower standard deviations, 
potentially showing significance where the smaller groups failed. Larger 
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groups, as well repeated measures, gets much more expensive, due to the 
additional MRI scans required, and the additional animals in larger groups.   
In addition to the alternatives presented above, a different model could 
have been used, as an example, that of a cryoinjury model.  Here a probe, 
typically exposed to liquid nitrogen, is used to freeze and kill the tissue.  This 
results in a very reproducible sized defect determined by the size of the probe 
and the duration of contact with the heart.  It is, however, a less accurate 
model in looking at cell survival.  Cells in the heart defect die as a result of the 
freezing, not as a result of blood flow.  This makes it impossible to view 
increases in cell survival by staving off apoptosis, or necrosis as a result of 
nutrient depletion and waste accumulation.  It can be used for looking at 
remodeling of the heart, as well as neovascularisation.   
While not directly related to the results, it is possible that a longer 
interval between treatment and data collection should have been used.  
Remodeling of the heart after an infarct is typically seen as two end results.  
First is the redistribution of stresses in the heart as a result of the lost tissue 
and contractility.   Second is dilation of the ventricle resulting in the same 
stroke volume even at the lower ejection fraction (2).  Stresses in the heart 
were not analyzed, but based on the stroke volume data, 4 weeks was 
insufficient for full remodeling.  Noninfarcted controls showed average ejection 
volumes of 0.12±0.04 mL; treated animals showed ejection volumes ranging 
from 0.06±0.01 to 0.09±0.01 mL with a positive correlation between ejection 
fraction and ejection volume.   
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The results of the biodistribution showed that the PoligoGel performed 
as expected in retaining the cells at the site of the injection, with 15 times the 
number of cells retained, based on the experimental results.  With the 
improved retention, it is dissapointing that no benefit to the hearts’ function 
was seen, concidering that in other studies cells alone have shown 
improvement the heart function (18). The inclusion of a different growth 
factor, such as FGF or VEGF, should have made a more significant difference on 
the results.  The lack of improvement after such success in retaining the cells is 
puzzling, but there are several possible explanations.  First, although the cells 
were retained in greater numbers at 24 hours, it is possible that at longer time 
points, cells were lost at equal numbers.  This could occur as a result of cells 
that are released from the gel as it degrades being lost from the heart in a 
fashion similar to that of cells injected without the scaffold.  The PoligoGel 
could even exacerbate this, as it has been shown to impede cell adhesion in 
vitro.  This same effect of impaired cell adhesion could also lead to poorer 
chemotaxis of the animal’s own cells to the site of the infarct.  While there 
were no data collected to support either of these possibilities, none was 
collected to refute it either; and neither would explain why the growth factors 
produced by the stem cells were not more effective.  Gene vectors for VEGF 
injected into the heart were shown to be effective in some studies (19, 20); 
others studies did not show therapeutic results (21).  There are two main 
differences between the VEGF studies and that presented here. First, the 
growth factor of choice here is different.  PDGF-C has not been known as long, 
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or studied as well as other growth factors, such as VEGF, or FGF.  Despite 
promising results prior to the animal work, it may have been a poor choice, due 
to lower cellular activation, higher effective doses required, or other reasons.  
Secondly, different populations of cells were transfected, and presumably 
different numbers of transfected cells were resident in the heart after the 
procedure.  While the growth factors produced by either population should be 
identical, the rate of production between individual cells of different origins 
can vary.  MSCs were shown to have a transfection rate of about 10%, leading 
to an estimate of 30,000 transfected cells being injected to the heart.  Direct 
injection of a gene vector into the heart could potentially yield a higher 
number of transfected cells, leading to the improved outcomes.  If the number 
of transfected cells is the limiting factor, it could be overcome by cell sorting.  
Dual encoding plasmids, which express both the therapeutic gene, as well as a 
marker, such as GFP, can be used for the transfection.  Flow cytometry can 
then be used to isolate transfected cells, allowing for the injection of a fully 
transfected population.    
5.6 Conclusions 
As established in the introduction, the use of stem cell and growth 
factors for the treatment of infarcts has shown potential in multiple instances, 
both individually, as well as combined.  This potential was not realized here in 
the treatment of the infarcts.  Despite a lack of improvement in the heart, 
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PoligoGel did work as intended in retaining cells in the injection site, at least 
in the short term.   
Several changes should be made to better ascertain the true potential of 
using a scaffold for injecting cells: first, an improvement in the surgical 
reproducibility; second, modified analysis, either by increased sample size, or 
taking repeated measurements; third, working with a growth factor previously 
proven to improve heart function.  These changes should permit the acquisition 
of data showing the improved outcome with the use of cells injected in a 
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Figure 5.1 Example images of MRI data taken from a rat receiving cells in 
PoligoGel as a treatment.  Slice shown is from about 6 mm above the apex of 
the heart.  Pixel size for the images was about 0.15 mm along the x-axis, and 
0.26 mm along the y-axis.  The top image shows the raw images, while the 
bottom has had the contours of the inner and outer walls of the ventricle 






Figure 5.2 Ejection fraction results of the rat heart after ligation.  While 
all groups were different from the nonligated control (Thoracotomy), there 
were no differences between the other groups.  Error bars indicate the 





Figure 5.3  Wall thickness between treatment groups of rats.  All the 
infarcted tissues saw decreases in thickness of the tissue, as well as loss of 





Figure 5.4 The change in the thickness of the ventricular wall for sector 
8 of the heart that includes infarcted tissue.  There was very little 
contractibility in the infarcted tissue.  All of the infarcted tissue was 
significantly different from the control (p<0.0001) but there was no difference 
between experimental groups.   
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Figure 5.5 Volumes of the heart at end systole and diastole.   There were 
no differences between the groups for either measurement.  Error bars 




Figure 5.6 The stroke volumes for the different treatment groups.  All of 
the groups were different from the thoracotomy control; however, there was 
no difference between the experimental groups.  Error bars are the standard 






SYNOPSIS OF RESULTS, CONCLUSIONS, AND FUTURE 
PROSPECTS 
6.1 Synopsis of Results and Conclusions 
At the onset of this work outlined in Chapter 1, the hypothesis was 
three-fold.  First, MSCs could effectively be used as bioreactors for the 
production of growth factors, and produce an angiogenic response.  Second, a 
polymer scaffold could be found which could be used in conjunction with the 
MSCs without altering their intrinsic properties.  The third part of the 
hypothesis was that the use of the MSCs in the scaffold could effectively treat 
the heart following a coronary ligation.   
Genetically modified mesenchymal stem cells in a thermoreversible 
scaffold were shown to have potential for treatment for ischemic heart 
disease. Multiple growth factor containing plasmids were used with the MSCs 
and gave rise to proliferation and angiogenic responses in HUVEC, A7R5, and 
MSCs cell lines.  Neither the growth factors, nor the polymers used for 
transfection, showed any adverse effects on the stem cells ability to 
differentiate; it also did not cause differentiation in the cells.   
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After the testing of multiple hydrogels, PoligoGel was found to be non-
toxic and effective as a potential scaffold for the MSCs.  A primary concern 
with the scaffold was the effect it may have on the stem cells, as the growth 
substrates can alter gene expression in the cell (1-3).  This was not seen to be 
an issue with the scaffold used here.  The encapsulation by PoligoGel with or 
without an accompanying transfection did not induce differentiation, or have 
any effect on the ability of MSCs to differentiate into either adipogenic fates, 
or osteogenic fates (4). 
The combined therapy involved the study of heart function in a rat 
ligation model.  It was expected that all groups treated with MSCs would have 
improved heart function over the untreated infarct group, and the addition of 
PDGF-C via transfection of the cells, and the use of a scaffold would yield 
further improvements.  However, MRI results did not yield any significant 
difference in the treatment groups.  Biodistribution indicated that the scaffold 
of PoligoGel was effective in retaining the cells at the heart, as measured at 24 
hours.  In fact, the increase was over 15-fold over cells injected without the 
aid of a scaffold.  The single largest issue preventing statistical significance in 
the study was the large standard deviation in the data.  Infarcts varied widely 
from animal to animal, making it difficult to view any effects of the different 
treatments.  While treatment groups had higher averages than the untreated 
control, there was no statistical difference between any of the infarcted 
groups.   
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There are several places where changes could be made in the study that 
may have improved the outcome.  To start with is the selection of the growth 
factor, PDGF-C.  While this growth factor outperformed the others tested in 
vitro, its use in vivo did not produce any results in this study.  This may have 
been due to inadequate gene expression, thereby failing to initiate a response 
of the surrounding cells.   The insufficient expression could have been in the 
resulting concentration of PDGF-C around the wound, or the expression may 
not have been of sufficient duration to produce a therapeutic effect after 
initial exposure. The comparisons of growth factors did not extend into the 
animal work.  Additional control groups using alternate growth factors, VEGF 
would be one possibility, would be needed to see if the combined therapy was 
ineffective as a result of the choice of the growth factor.   
While PoligoGel did retain cells at the injection site at 24 hours, and has 
been used as a small molecule delivery vehicle in vivo, it may have had 
unanticipated and unintended consequences.  While cells in the short term 
were at the heart, they would in most cases have still been in association with 
the scaffold, which was shown to limit cell attachment.  It is possible that with 
the PoligoGel at the heart, the injected MSCs would have been unable to 
attach to the extracellular matrix and integrate with the heart as the polymer 
degraded and the gel loses integrity.  The gel may also have prevented cells’ 
movement into the infarcted region from local populations of cells, mitigating 
any benefit from the injected cells directly, but would not have affected the 
extracellular delivery of the growth factors.  It is also possible that the gel 
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itself had adverse consequences when injected at the heart; there is no reason 
to suppose this alternative, but the data cannot rule it out.  The spherical 
morphology of the cells in the gel is not believed to be an issue for several 
reasons.  First, cells in vitro did not show adverse reactions to the gel while 
spherical; they remained viable out past 7 days, and also continued to produce 
proteins when transfected for over 4 days.  Second, once removed from the 
gel, they resumed growth and proliferation.   
The combined in vivo study had several shortcomings, some as a result 
of inadequate design; others were only apparent in hindsight.   Large variation 
in the infarcts prevented the illumination of any significant differences in the 
groups.  The large variation was at least in part due to surgical technique.  
Others using the same model had standard deviations about 1/3 as large as 
achieved here (5).  A repeated measures analysis would have been a more 
robust method of collecting data.  This would have helped to limit variation in 
infarct size from impairing the ability to see trends in the data.  Individual 
animals could have had MRIs performed between days 3-7 once animals have 
recovered from the initial trauma of the surgery.  These data would have then 
been compared to the data collected at the follow-up at 4 weeks postinfarct.  
Individual improvement or decline would not be lost in the differences between 
animals.  Several additional control groups would have been of interest once 
the date came back.  One of these would be the use of a different, proven 
growth factor; VEFG would be the likely candidate.  This was neglected in large 
part due to the anticipated therapeutic effect of cells alone, which others have 
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seen (6).  The use of a different gel, such as fibrin, would have also been a 
valid comparison.  However, without improvements in the variation between 
animals, it is quite possible that neither of these, or any other additional 
control groups, would have added anything to the experiments, while raising 
both the financial and animal costs.   
6.2 Future Work 
While the present work shows promise for the treatment of heart 
disease, there is other work that could be done to further the understanding of 
the treatment.  Although PDGF-CC showed consistently high results for 
angiogenesis in vitro, a different growth factor or combination of growth 
factors may be more effective in vivo.  In addition to the choice of growth 
factor, the method of transfection may benefit from additional analysis.  Using 
PEI, only 7-15% of the cells are transfected.  Increased expression in the cells, 
either by refinement of the transfection, or by sorting of the cells, could also 
yield greater therapeutic benefit.  Refinement of transfection is an ongoing 
process, with new polymers constantly being developed by many different labs.  
Sorting of transfected cells via FACS can be accomplished by labeling the 
plasmid or polymer prior to transfection, or by the use of a dual expression 
plasmid encoding green fluorescent protein, or protein marker.  An additional 
point of consideration is the differentiation of the stem cells to a cardiac fate 
prior to use in the heart (7).  This has not been easy to accomplish in vitro (8). 
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In addition to coronary ischemia, there are many other possible 
applications for transfected stem cells in a scaffold.  These include stroke (9), 
cancer (10), diabetes (11), and neurological disorders such as Parkinson’s (12, 
13).  
6.2.1 Stroke 
Current treatments for stroke using stem cells have shown improved 
outcomes for patients receiving treatment (9, 14).  However, these treatments 
have used an IV catheter for the infusion of the cells into the patent, and not a 
local injection.  Due to the temperature-dependent gelation, it would be 
difficult if not impossible to inject via catheter without a gel forming prior to 
delivery at the desired location.  It may be possible to modify PoligoGel to add 
a second response stimulus, such as pH, or enzymes which would delay the 
onset of the gel formation until after it has reached the desired location (15, 
16).   
6.2.2 Cancer  
There are multiple genes that have been used for gene therapy 
treatment of cancers.  Some of these genes are soluble, such as growth factor 
receptors (17, 18), and interleukins (19).  These could be delivered in 
transfected stem cells and retained at the cancer site.  This would be most 
effective after a lumpectomy, or even a biopsy.  It would also be possible to 
treat cancer using stem cells transfected with suicide genes (20) relying on 
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paracrine factors to induce apoptosis in surrounding cells.  Others have 
transfected cells with replication-competent viruses prior to treating cancer 
(21, 22); this can help minimize the neutralization of viral particles by the 
immune system before they can infect cancer cells.  Any number of genes 
could be used with this type of approach.   
6.2.3 Diabetes 
Cell-based therapies for the treatment of diabetes have suffered from 
problems of low cell viability following transplantation (23).  One proposed 
method of overcoming this is to use a rechargeable system, where cells and 
scaffold can be replaced as efficacy wanes (24).  A rechargeable system such as 
proposed by Bae et al. coupled with modified stem cells expressing insulin 
driven by a glucose responsive promoter (25) could be an effective treatment 
for diabetes, and similar work has shown promise (11). 
6.2.4 Neurological Disorders 
Unlike stroke, treatment for degenerative neurological disorders may 
require access to the brain, such as for the implantation of electrodes for deep 
brain stimulation (26).  This access allows for the simple injection of stem cells 
in PoligoGel.   
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6.2.5 Additional Possibilities 
There is also the possibility of using the gel to deliver more than just 
transfected stem cells. Multiple studies have demonstrated the benefit of using 
multiple growth factors to achieve better outcomes (27, 28).  Results have 
demonstrated the benefits of a multiple growth factor delivery approach.  Two 
different populations of transfected cells could be grown and combined; or a 
recombinant protein could be placed in the gel.  It may even be possible to 
place DNA / polymer complexes in the gel to be released and transfect the 
surrounding tissue. PoligoGel has already been used for the delivery of small 
molecules (US Patent 7,655,735 B2). 
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